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1. Summary 
Celiac disease (CD) is an enteropathy caused by permanent intolerance to 
gluten/gliadin, in genetically susceptible individuals (Sollid 2000; Shan et al., 2002). 
This pathology is characterized by the presence of anti-tissue transglutaminase 
antibodies in the serum and by damage at the level of the small intestine with villous 
atrophy, intraepithelial lymphocyte infiltration, chronic inflammation and activation of 
lamina propria T cells. Nevertheless, patients go into remission when they are put on a 
gluten-free diet (Sollid, 2002) The mechanisms by which gluten/gliadin damages the 
intestinal mucosa of coeliac patients have not been elucidated. Different hypotheses 
have been proposed to explain the origin of the mucosal damage. Some reports include 
a direct toxic effect of gliadin on intestinal mucosa (Auricchio et al., 1990; Maiuri et al., 
1996). Most observations favour a dysregulated immune response to gluten-derived 
peptides in coeliac patients. Toxic gluten peptides are absorbed across the epithelium, 
presented in associated with HLA class-II molecules by macrophages in the lamina 
propria and recognised by gliadin antigen specific CD4+ T cells (Marsh, 1992; Sollid, 
2000). As a result, secreted mediators, including interferon-γ (IFN- γ), may cause 
activation of macrophages which, in turn, produce pro-inflammatory cytokines 
contributing to the damage of the mucosal matrix (Przemioslo et al., 1994; Kontakou et 
al., 1995; Nilsen et al., 1995; Pender et al., 1996). It has been reported that nitric oxide 
(NO) and prostaglandins (PGs) may play an important role in the mucosal lesion 
(Beckett et al., 1999; Lavo et al., 1990). High levels of nitric oxide products 
(nitrate/nitrite) in the urine of children with active CD have been correlated with the 
expression of inducible nitric oxide synthase (iNOS) in the small intestine (Holmegren 
Peterson et al.,1998; van Straaten et al., 1999; ter Steege et al., 1997). Increased 
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amounts of prostaglandin E2 (PGE2) in homogenized small bowel biopsies from patients 
with active CD have been detected (Lavo et al., 1990). Recently, it has been reported 
that lamina propria cells from coeliac patients produce high levels of cyclooxygenase-2 
(COX-2) (Kainulainen et al., 2002). It has been shown that in CD both enterocytes and 
cells with macrophage-like morphology in the lamina propria are responsible for 
increased iNOS expression (ter Steege et al., 1997). Recent report has shown that gluten 
or gliadin and their proteolytic fragments enhanced NO production and iNOS mRNA 
level in mouse peritoneal macrophages stimulated with IFN-γ (Tuckovà et al., 2000). A 
common paradigm for the pathogenesis of CD is that several genes whose expression is 
induced in the inflamed mucosa, such as those encoding for iNOS and COX-2, contain 
κB sites for Nuclear Factor-κB (NF-κB) (Xie et al., 1994; Yamamoto et al., 1995). NF-
κB has been identified in epithelial cells and lamina propria macrophages from biopsy 
specimens or cultured cells of patients with Crohn’s disease, ulcerative colitis and 
unspecific colitis (Schmid and Adler, 2000). Recently it has been assessed IRF-1 and 
STAT-1α expression in the mucosa of active CD (Mazzarella et al., 2000). The 
promoter region of the iNOS gene has been characterized in different species, including 
human, rat and mouse (Xie et al., 1993; Chu et al., 1995; Eberhardt et al., 1996). 
Sequence analysis of promoter revealed the presence of consensus motifs for binding of 
transcription factors, such as NF-κB, interferon regulatory factor-1 (IRF-1) and signal 
transducer and activator of transcription-1α (STAT-1α), which are essential for the 
iNOS induction by IFN-γ (Kamijo et al., 1994; Martin et al., 1994; Weisz et al., 1994; 
Gao et al., 1997; Kim et al., 1997). The aim of this present doctoral thesis was to 
investigate the molecular mechanisms involved in the pathogenesis of celiac disease. In 
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the first phase of the study, I have investigated ex vivo NF-κB activation in intestinal 
biopsy specimens from patients with active CD. In the second phase of the study, I have 
investigated in vitro the effect of gluten-derived peptides on iNOS gene expression in 
RAW 264.7 macrophages stimulated with IFN-γ, a murine cell line. In the third phase of 
the study, I have further investigated in vitro the synergistic induction of iNOS gene 
expression by gliadin plus IFN-γ focusing on the differential kinetics of activation and 
expression of NF-κB, IRF-1 and STAT-1α.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Celiac disease 
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2.1 Introduction 
Celiac disease (CD) is a gluten sensitive entheropathy in which ingested wheat gluten or 
related proteins from rye and barley are not tolerated (Trier, 1991). CD has a chronic 
nature where particular HLA alleles are overrepresented among the patients (Thorsby, 
1997). Usually these disorders are multifactorial, due to HLA genes wrong expression 
and environmental factors. Moreover the expression of CD is strictly dependent on 
dietary exposure to gluten and similar cereal protein (Trier, 1991). Patients go into 
complete remission when they are put on a gluten-free diet and relapse when gluten is 
reintroduced into the diet. From this point of view CD is the unique, among the chronic 
inflammatory HLA-associated diseases, in that a critical environmental factor has been 
identified. CD is mostly recognized among Europeans and presents in early childhood 
with classic symptoms including chronic diarrhoea, abdominal distension and failure to 
thrive (Schmitz, 1992). Anyway the disorder may also present later in life with 
symptoms that tend to be more vague. 
CD patients have increased levels of serum anti-bodies to a variety of antigens, 
including gluten and the auto-antigen tissue transglutaminase (tTG) (Dieterich et al., 
1997). Testing of serum antibodies to gluten and tissue tTG is utilized to predict CD. 
The final diagnosis rests on the demonstration of typical mucosal damage by 
histhological examination of small intestinal biopsies. Current treatment of CD is a 
lifelong exclusion of gluten from the diet. Patients who do not observe this diet may 
have complications including anemia, infertility, osteoporosis and intestinal lymphoma. 
Moreover untreated CD is associated with increased mortality (Maki and Collin, 1997). 
The lesion in CD is localized in the proximal part of the small intestine and is 
characterized by villous atrophy, crypt cell hyperplasia, lymphocytic infiltration of the 
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epithelium and increased density of various leukocytes in the lamina propria (Figure 1). 
These alterations have been classified into three stages: 
- infiltrative lesion, chraracterized by infiltration of small nonmitotic lymphocytes in 
the     villous epithelium 
-  hyperplastic lesion, similar to infiltrative but in addition has hypertrophic crypts 
whose epithelium may be infiltrated by lymphocytes 
- destructive lesion, in which villi appear totally atrophic. 
Oral challenge with gluten have demonstrated that these stages are dynamically related. 
Many populations participate at mucosal lesion: enterocytes, intraepithelial 
lymphocytes, lamina propria leukocytes and the extracellular matrix (ECM). 
In CD there is a loss of epithelial cells and increased proliferation of epithelial cells in 
the crypts. Both these factors have been used to explain the villous atrophy found in CD 
(Booth, 1970). 
The two phenomena probably reflect increased apoptosis of enterocytes whereas the 
increased enterocyte proliferation in the crypts may be due to an increased production of 
keratinocyte growth factor (KGF) by stromal cells (Bajaj-Elliot et al., 1998). 
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 This population returns to normal when gluten is removed from the diet while the in the 
normal human intestine occur three major lineages of intraepithelial lymphocytes 
(IELs); the most prominent as the TCRαβ+ CD8+ CD4-. TCRγδ+ remains at elevated 
levels. However both the lineages express the Ki67 proliferation marker, suggesting 
intraepithelial proliferation of both populations in CD (Halstensen and Brandtzaeg, 
1993a). Activated human IELs are able to produce a number of cytokines including 
IFN-γ, IL-2, IL-8 and TNF-α which are known to have a lytic potential (Lundqvist et 
al., 1996). A marked infiltration of TCRαβ+ T cells appears in the lamina propria in the 
active lesion. These cells are mostly CD4+ and carry a memory phenotype. Moreover, 
there seems to be a particular increase in cells producing IFN-γ since mRNA for IFN-
γ has been found to be increased more than 1000 fold in untreated disease (Nilsen et al., 
1998). A characteristic of CD lesion is an accumulation of IgA, IgM and IgG producing 
plasma-cells. In the normal mucosa a high number of macrophage/dendritic cells which 
express abnormally HLA genes. Furthermore, increased ECM degradation has been 
suggested to play a role in the villous atrophy. Infact this is supported by the 
demonstration of a decreased ratio of cells expressing collagen I and tissue inhibitor of 
metalloproteinase-1 (MMP-1) and -3 mRNA in untreated CD (Daum et al., 1999). 
Expression of MMP-1 and MMP-3 mRNA is mainly localized to subepithelial 
fibroblasts and macrophages. It is likely that the increased expression of 
metalloproteinases is related to activation of mucosal T cells. 
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2.2 Molecular mechanisms 
2.2.1 Genetic aspects 
A high prevalence rate among first degree relatives of CD patients indicates a strong 
genetic influence on susceptibility to develop CD (Ellis, 1981). This strong influence is 
further supported by a high concordance rate in monozygotic twins (Polanco et al., 
1981). 
CD was first found to be associated with the HLA class I molecule B8. Later stronger 
association were found to the HLA class II molecules DR3 and DQ2, both containing 
the B8-DR3-DQ2 or the B18-DR3-DQ2 extended haplotypes (Alper et al., 1987; 
Congia et al., 1992). CD is also associated with DR7. In many studies patients have 
been shown to carry either the DR3-DQ2 haplotypes or are DR5-DQ7/DR7-DQ2 
heterozygous. Probably CD patients with these DR-DQ combinations share the genetic 
information conferring CD susceptibility (Sollid and Thorsby, 1993). It can be argued 
that susceptibility for CD depends on an interaction between at least two genes on the 
DR3-DQ2 haplotype that are reunited in DR5-DQ7/DR7-DQ2 heterozygous individuals 
(Figure 2). Theoretically this gene interaction could involve any HLA-linked genes in 
the DQ region. However, complete sequencing of an 86-kb genomic fragment spanning 
the DQ subregion of the DR3-DQ2 haplotype failed to identify genes other than DQA1 
and DQB1 in this region (Ellis, 1997). Furthermore, the DQA1 and DQB1 are very 
good candidates because their products interact by forming a class II heterodimer and 
because they are situated close to the putative recombination site. This evolutionary 
consideration together with the fact that most CD patients share a particular pair of 
DQA1 and DQB1 genes located either in cis or in trans are strong arguments that these 
alleles jointly confer susceptibility to CD.  
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Genes located in the HLA gene complex other than DQ might also contribute to CD 
susceptibility. Association to particular DP alleles have been reported in different 
population, but many of these association can be explained by linkage disequilibrium 
between the involved DP and the DQA1 and DQB1 alleles (Sollid and Thorsby, 1993). 
Studies of Irish CD patients have indicated an additional predisposing role of TNF 
genes, an association independent of DQ2 that has been demonstrated using a 
microsatellite polymorphism situated near rhe TNF genes (McManus et al., 1996). 
Moreover, a polymorphism of the TNF-α gene promoter has been demonstrated to be a 
component of the DR3-DQ2 haplotype. Other studies failed to demonstrate the finding 
of a DQ2-indipendent association of the TNF microsatellites but there could be a 
discrepancy related to population differences. Thus available data suggest that 
susceptibility to develop CD is primarily associated to two conventional peptide-
presenting DQ molecules DQ2 and to a lesser extent DQ8. An issue to be clarified is 
whether there are additional molecules encoded by unidentified genes in the HLA gene 
complex that also contribute to the genetic predisposition for CD. However any effect 
of these additional genes is likely to be moderate. A key question for the understanding 
of the molecular basis for CD is therefore to define the functional role of the DQ2 and 
DQ8 molecules. Peptides binding to DQ2 have anchor residues in the relative positions 
P1, P4, P6, P7 and P9 (Johansen et al., 1996; van de Wal et al., 1997). The binding 
motif of DQ8 is different from that of DQ2, but DQ8 also dispays a preference for 
binding negatively charged residues at several positions (Figure 3). Anyway both the 
DQ2 and DQ8 molecules share a preference for negatively charged residues at some of 
their anchor positions. The DQ2 and DQ8 molecules could confer susceptibility to CD 
by presenting disease-related peptides in the target organ or alternatively by shaping the 
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T cell repertoire during T cell development in the thymus. This issue has been addressed 
by studies of T cells derived from the celiac lesion. Stimulation of small intestinal 
biopsy specimens with a peptic/tryptic digest of gluten induces rapid activation of the T 
cells in the lamina propria of CD patients, but not of non-CD control-subjects 
(Halstensen et al., 1993b). Gluten-reactive T cells can be isolated and propagated from 
intestinal biopsies of CD patients but not from non-CD controls (Molberg et al., 1997). 
These T cells are CD4+ and use the αβ TCR. Importantly, T cells isolated from biopsy 
specimens of patients carryiing the DR3-DQ2 haplotype typically recognize gluten 
fragments presented by the DQ2 molecule rather than the other HLA molecules carryed 
by the patients (Lundin et al., 1994). Both DR3-DQ2-positive and DR5-DQ7/DR7-
DQ2-positive antigen-presenting cells are able to present the gluten antigen to these T 
cells. Interestingly, gluten-specific T cells can also be found in the peripheral blood. 
These T cells are restricted either by DR, DP or DQ molecules and they do not therefore 
display the predominant DR, DP or DQ restriction observed for gluten-specific T cells 
from the intestinal mucosa (Gjertsen et al., 1994).  
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One explanation for this could be that the majority of gluten-specific T cells of 
peripheral blood recognize epitopes different from those recognized by T cells of the 
small intestine. Studies of lamina propria T cells in situ have indicated that gluten-
reactive T cells have a cytokine profile dominated by IFN-γ. This notion is sustained by 
the characterization of gut-derived DQ2 and DQ8-restricted gluten-specific T cell 
clones. These T cells uniformly secrete IFN-γ at high concentrations and some produce 
IL-4, IL-5, IL-6, IL-10, TNF-α and TGF-β (Nilsen et al., 1995). 
 
2.2.2 T cells activation by gluten peptides 
Wheat gluten is a mixture of numerous proteins grouped into the gliadin and glutenin 
fractions. These proteins serve as a source of nitrogen and carbon for the growing 
seedling during germination. A vast sequence heterogeneity among gliadin and glutenin 
probably reflects that these proteins have been subjected to few structural constraints 
during evolution. Generally, gluten proteins contain a large percentage of proline and 
glutamine residues, while many other amino acids, including aspartic and glutamic acid, 
are unusually scarce. Feeding experiments have demonstrated that the gliadin fraction 
can precipitate CD (van de Kamer et al., 1953), whereas the role of glutenin is still 
inconclusive. Proteins of the gliadin fraction can be subdivided according to their 
sequence into the α-, γ- and ω-gliadins (Shewry et al., 1992) (Table 1). A large number 
of different gliadins exist within each of these gliadin families. Estimates suggest that as 
many as 50 to 150 different α-gliadin genes may be present in a single wheat cultivar 
(Anderson et al., 1997). For the work of identifying peptide fragments recognized by T 
cells, the complexity of this antigen presents a big challenge.  
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The stimulatory capacity of gliadin preparations for gliadin-specific intestinal T cells is 
significantly enhanced following treatments at high temperatures and low pH (Lundin et 
al., 1997). These conditions are known to cause nonspecific deamidation of glutamines 
to glutamic acid and many thus convert gliadin from a protein with very few peptides 
with the potential to bind DQ2/DQ8 into one with many such. Five unique epitopes of 
gluten that are recognized by gut T cells have been identified: three restricted by DQ2 
(Sjostrom et al., 1998) and two restricted by DQ8 (van de Wal et al., 1999). The first 
ones fail to stimulate T cells in their native form but are potent antigens when a single 
glutamine residue is exchanged with glutamic acid in certain positions. The second ones 
recognition is augmented by introduction of negatively charged residues (van de Wal et 
al., 1998). These data demonstrate that most gluten-specific intestinal T cells from CD 
patients recognize gluten proteins only after they have undergone deamidation. 
Moreover, the results with the gluten epitope demonstrate that intestinal T cells can 
recognize gluten proteins other than gliadins (van de Waal et al., 1999). The 
deamidation of gliadin in vivo may take place in the acidic environment in the stomach 
(Sjostrom et al., 1998) or, altenatively, it can be mediated by the enzyme tissue 
tansglutaminase (tTG) which is expressed in many different tissues and organs 
(Molberg et al., 1998). In the small intestine it is expressed just beneath the epithelium 
in the gut wall (Figure 4). This enzyme is present both intracellularly and extracellularly 
and in the extracellular environment plays a role in the extracellular matrix assembly, 
cell adhesion and wound healing (Bruce et al., 1985).  
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The calcium-dependent transglutaminase activity of tTG catalyzes selective cross-
linking or deamidation of protein-bound glutamine residues (Folk, 1983) and appears to 
carry out an ordered deamidation of some few specific glutamines (Molberg et al., 
1998).  
Interestingly, the deamidation of glutamines that are not targetedby tTG can be 
deleterious for T cell recognition (Quarsten et al., 1999). It is intriguing to hypothesize 
that tTG plays a central role in the selection of gliadin T cells epitopes. This idea is 
supported by the observation that the intestinal T cell response to α-gliadin in adults is 
focused on a single deamidated glutamine that is targeted by tTG (Arentz-Hansen et al.,  
1999). The IgG and IgA serum antibodies to tTG (anti-endomysial antibodies) are a 
hallmark of CD and detection of serum IgA tTG-antibodies is utilized to predict the 
disease (Sulkanen et al., 1998). An important physiological role of tTG is the catalysis 
of isopeptide bond formation between glutamine and lysine residues. In vitro treatment 
of gliadin fragments with tTG leads to some gliadin fragments becoming covalently 
attached to tTG by autocatalysis (Molberg et al., 1998). tTG specific B cells may 
selectively bind and internalize gliadin-tTG complexes via specific surface 
immunoglobulis. The gliadin fragment may finally be processed and presented by DQ2 
or DQ8 to the gliadin-specific T cells, thereby providing cognate help for B cell 
maturation, isotype switching and antibody secretion. This observation could explain 
why tTG antibody-levels in CD are dependent on the presence of gliadin in the diet 
because its removal is able to abolish the T cell help needed for antibody production. 
It is demonstrated that CD4+TCRαβ+ T cells in the lamina propria are central for 
controlling the immune response to gluten that produces the immunopathology of CD. 
The knowledge of the events downstream of T cell activation is, however, still 
 24
incomplete. Anyway, the characterization of mechanisms operating in the model of 
human fetal gut explant cultures, where activation of T cells induces villous atrophy and 
hyperplasia of the crypts, has provided interesting clues and indicated some major 
pathways (Pender et al., 1997). Recent in vitro organ cultures studies have indicated 
that gluten exerts additional immune relevant effects independent of T cell activation 
(Maiuri et al., 1996; Maiuri et al., 1998), some of which have rapid kinetics and 
conceivably the direct effects of gluten may facilitate subsequent T cell responses. 
Cytokines produced by lamina propria CD4+ T cells may be involved in the increased 
crypt cell proliferation and the increased loss of epithelial cells. Moreover, IFN-γ 
induces macrophages to produce TNF-α which, in turn, activates stromal cells to 
produce KGF which causes epithelial proliferation and crypt cell hyperplasia (Bajaj-
Elliot et al., 1998) (Figure 5). IFN-γ and TNF-α can jointly have a direct cytotoxic 
effect on intestinal epithelial T cells. Alterations of the ECM can also distort the 
epithelial arrangement, as the ECM provides the scaffold on which the epithelium lies. 
Infact enterocytes adhere to basement membrane through ECM so that modifications or 
loss of the basement membrane can result in enterocyte shedding. The increase of ECM 
degeneration might be important for the mucosal transformation found in CD (Daum et 
al., 1999). Also the increased production of MMPs by subepithelial fibroblasts and 
macrophages is likely to be directly or not induced by cytokines that are released from 
activated T cells.  
 25
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Instead very few is known about the autoantibodies: the endomysial antibodies can be 
involved in the disease development by blocking interactions between mesenchymal 
cells and epithelial cells during the migration of epithelial cells and fibroblasts from the 
crypts to the tips of the villi.  
tTG is necessary for activation of TGF-β (Nunes et al., 1997) which is known to affect 
the differentiation of the intestinal epithelium (Halttunen and Maki, 1999), to stimulate 
the ECM (Bonewald, 1999) and to regulate the function of many immune competent 
cells within the gut microenvironment (Letterio and Roberts, 1998). Moreover it has 
been demonstrated that tTG is involved in attachment of fibroblasts to the ECM 
(Verderio et al., 1998) thereby suggesting that the autoantibodies could also be involved 
in lesion formation by perturbing important contacts between fibroblasts and ECM 
components. In addition tTG autoantibodies may modulate the deamidating activity of 
tTG in either an inhibiting or a promoting fashion (Sollid and Scott, 1998).   
 
            2.2.3 A new mechanism 
In the early 1960s it was suggested that gliadins, or peptic-tryptic digests, had a directly 
toxic effect on the mucosa of patients with active CD. To explain this research some 
scientists proposed “the lectin hypotesis” which suggested that gliadins interacted 
directly with glycoproteins in the epithelial cell membrane. Moreover, this hypothesis is 
supported by the presence of specific antigliadin antibodies and disease specific auto-
antibodies against connective tissue components such as endomysium and reticulin, 
along with the presence of activated lymphocytes in the mucosa of untreated patients. 
However, the most compelling evidence for an immune-mediated pathogenesis is the 
extremely strong association of the disease with HLA class II molecules (Sollid and 
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Thorsby, 1993). Gliadin-derived peptides may be processed for presentation by HLA 
class II molecules to helper T cells. Once activated T cells might orchestrate the 
changes leading to entheropathy (Gjertsen et al., 1994). In a recent study mucosal 
biopsy specimens were taken from the duodenum of patients or controls and cultured 
for approximately 24 hours with digest of gliadin or control prolamins from maize, 
which are known not to be toxic. The results showed not only the expected changes 
accompanying immune activation but also an early, immediate effect of gliadins on the 
tissue. Infact it was demonstrated that activated helper CD4+ T cells and macrophages 
migrated to the subepithelial compartment. HLA-DQ expression was up-regulated on 
mononuclear cells and the epithelium was invaded by CD8+ T cells. Furthermore, also 
disease specific antiendomysial antibodies were produced (Picarelli et al., 1996; Godkin 
and Jewell, 1998). Moreover, another recent study has shown that gliadin can directly 
interact with the extracellular protein transglutaminase (Dieterich et al., 1997). This 
enzyme catalyzes the transfer of an acil group from a specific Gln donor to a non 
specific Lys acceptor, resulting in protein cross-linking. This means that the 
antiendomysial antibody is directed to the transglutaminase itself, suggesting that T-cell 
epitopes in the gliadin provide help in driving the antibody response to both the gliadin 
and transglutaminase. Alternatively, the interaction between transglutaminase and 
gliadin may result in the expression of novel epitopes. Although the endomysial 
antibody may or may not have a direct role in the pathogenesis disease this study 
confirms that gliadin directly interacts with components of mucosa (Godkin and Jewell, 
1998). 
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3. Nitric oxide (NO) 
NO is one of the smallest biologically active messenger molecules. It is also one of the 
first gaseous biological messenger which has a wide range of physiological and 
patophysiological actions in mammalian cells. NO is synthesized by the enzyme nitric 
oxide synthase (NOS) via the 5-e oxidation of one of the chemically equivalent 
guanidino nitrogens associated with L-arginine (Figure 6). NO is involved in the control 
of cardiovascular, central and peripheral nervous and immune systems (Figure 7). In 
vivo NO reacts with oxyhemoglobin, resulting in the formation of its stable metabolite 
nitrite (Butler and Williams, 1993) but can also react with superoxide anion (O2-) to 
form peroxynitrite (ONOO-), a relatively stable product. Moreover, NO can react with 
thiols to form S-nitrothiols, such as S-nitrosocysteine and S-nitrosoglutathione (Figure 
8). Many of the biological actions of NO are mediated through the guanylate-cyclase-
cGMP system. NO diffuses to adjacent cells, activates soluble guanylate cyclase by 
binding to the iron on its heme component and moves the iron out of the plane of the 
porphyrin ring. This mediates some of the biological effects of NO such as the 
relaxation of vascular and nonvascular smooth muscle, inhibition of platelet adhesion 
and aggregation, inhibition of the chemotaxis of polymorphonuclear cells and the signal 
transduction pathways in the central and peripheral nervous systems (Murad et al., 
1987; Schmidt et al., 1993). It is now well estabilished that NO has also a number of 
cGMP-independent actions. The cytotoxic effects of NO involve the inhibition of tumor 
cell NADH ubiquitinone reductase, NADH-succinate oxidoreductase, cis-aconitase and 
all iron-sulfur prosthetic groups of the enzymes that contain them (Nathan, 1992).  
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cGMP-independent effects of NO on other enzymes, such as cyclooxygenase (COX) 
have also been described in macrophages and islet cells (Salvemini et al., 1993). These 
effects may be related to the reaction of NO with the iron heme center in the active site 
of the enzyme. Thus NO, at high concentrations, inhibits COX activity (Stadler et al., 
1993) as well as the activity of NO synthase itself (Assreuy et al., 1993). NO can also 
inhibit the cativity of cytochrome p-450 enzymes in vivo and in vitro. In macrophages 
NO also inhibts vacuolar-type proton-ATPase with a subsequent impairment in 
phagocytosis, protein synthesis and antimicrobial activity (Swallow et al., 1991). 
Cytotoxicity caused by high local levels of NO can also be due to NO-mediated DNA 
damage, which is due to inhibition of ribonuclease reductase (Lepoivre et al., 1990; 
Kwon et al., 1991); it can also cause mutations by nitrosative deamination (Nguyen et 
al., 1992). Accordingly, NOS inhibitors inhibit the promotion of neoplastic 
transformation. 
Some of the oxidant/cytotoxic effects of NO are due to reaction of NO with O2- to form 
peroxynitrite ONOO-, with subsequent formation of NO2- and hydroxyl radical1 
(Beckman et al., 1990). It has been demonstrated that the majority of NO produced by 
activated macrophages is converted to ONOO-, through this reaction (Zhu et al., 1992). 
 
3.1 Nitric oxide synthases isoforms and nomenclature 
The nitric oxide synthases constitute a family with at least three distinct isoforms. In 
order of their molecular characterization, these include the neuronal (nNOS or NOS1) 
                                                 
1 Peroxynitrite has a half-life of 1.9 seconds at pH 7.4 and exists in equilibrium with 
peroxynitrous acid, as shown in the equation O2-. + NO. ONOO- + H+.  
ONOOH 
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(Bredt and Snyder, 1991; Nakane et al., 1993), inducible (iNOS or NOS2) (Xie et al.,  
1992; Lowenstein et al., 1992) and endothelial constitutive (ecNOS, NOS3) (Lamas et 
al., 1992; Janssens et al., 1992) NOSs. Their apparent molecular masses are 160, 130 
and 135 kDA, respectively (Table 2). Originally purified from neurons, cytokine-
induced macrophages and vascular endothelium (hence the designations nNOS, iNOS 
and ecNOS), the three isoforms are now appreciated to distribute across a wide 
spectrum of cell types and tissues. Furthermore, recent findings indicate that a cell may 
express more than one isoform of NOS (Radomski et al., 1990; Mehta et al., 1995) 
thereby complicating the interpretation of NO derived from any given cell. 
 
3.2 Biochemical functions 
The NOSs are well characterized as cytochrome P-450-like hemeproteins (Bredt and 
Snyder, 1991; White and Marletta, 1992). They can be broadly divided into a reductase 
domain at the COOH terminus and an oxidative domain at the NH2 terminus. The 
primary amino acid sequences of NOS isoforms share common consesus sequences 
binding site for calmodulin, NADPH, flavin-adenin dinucleotide (FAD) and flavin 
mononucleotide (FMN) (Bredt and Snyder, 1991; Lowenstein et al., 1992; Xie et al., 
1992). Each enzyme function has a dimeric protein in catalyzing the NADPH-dependent 
five-electron oxidation of L-arginine to generate NO. L-Citrulline is a by-product (Abu 
and Stuehr, 1993). Electrons are supplied by NADPH, transferred along the flavins and 
calmodulin and presented to the catalytic heme center (Stuehr and Ikeda, 1992). The 
NOS apoenzyme requires tetrahydrobiopterin, prosthetic heme (ferroprotoporphyrin 
IX), calmodulin, FMN and FAD as cofactors for monomer assembly and/or catalytic 
activity (Abu and Stuehr, 1993).  
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The nNOS and ecNOS isoforms are constituvely expressed, but enzyme activation 
requires stimulation of the calcium/calmodulin signalling pathway (Zhang and Vogel, 
1994). The synthesis and release of NO by constitutive NOS isoforms are rapid and do 
not depend on new protein synthesis. Calmodulin, in the presence of an elevated level 
of intracellular free calcium, activates constitutive NOS activity. In contrast the 
expression of iNOS is stimulated by cytokines or lipopolysaccharide (LPS) over a 
period of many hours. This process is dependent on new mRNA and protein synthesis 
(Vodovotz et al., 1994). Once it has been induced, this enzyme produces large amounts 
of NO and its activity is independent of intracellular calcium levels. Despite this 
difference in their dependence on calcium, all three NOS isoforms appear to be related. 
 
3.3 Genes encoding the three isoforms 
NOS cDNA from  many species have been cloned and functionally expressed. These 
include rat (Bredt and Snyder, 1991), mouse (Ogura et al., 1993) and human (Nakane et 
al., 1993) nNOS; mouse (Xie et al., 1992; Lowenstein et al., 1992), rat (Wood et al.,  
1993) and human (Geller et al., 1993a) iNOS and bovine (Nishida et al., 1992) and 
human (Janssen et al., 1992) ecNOS. Three distinct genes encoding the family of 
human NOS proteins have been identified and characterized. Analysis of these complex 
loci reveals that the mechanisms implicated in controlling mRNA expression and 
structure are unique for the different NOS isoforms. Human nNOS, iNOS and ecNOS 
are present on chromosomes 12, 17 and 7, respectively. Detailed analysis of genomic 
organization and exon/intron structure indicates a remarkably high degree of relatedness 
among the three genes (Hall et al., 1994). The only related gene in the human genome is 
cytochrome P-450 reductase. 
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3.4 iNOS gene: transcriptional and posttranscriptional regulation 
iNOS is, under physiological conditions, absent from mammalian cells and induced by 
proinflammatory stimuli such as bacterial LPS or cytokines or combinantions.  
Evidences suggest that induction of iNOS in a number of patophysiological conditions 
is part of an uncontrolled and deleterious immune activation, for inhibition of NOS 
exerts protective effects in these conditions (Nussler and Billiar, 1993). 
The human iNOS gene localizes to the 17q11.2-q12 region of chromosome 17 (Xu et 
al., 1994). This human locus has been a region of interest in cardiovascular disease, 
expecially hypertension.  
The iNOS gene consists of 26 exons and 25 introns spanning 37 kb of human genomic 
DNA (Chartrain et al., 1994). The full-lenght open reading frame is 3459 bp, encoding 
a protein of 1153 amino acids., a palindromic TNF-RE-like site and a liver-specific 
transcription factor consesus sequence, AABS (Chartrain et al., 1994; Nunokawa et al., 
1994). Sequence analysis of promoter revealed the presence of consensus motifs for 
binding of transcription factors, such as NF-κB, IRF-1, STAT-1α and nuclear factor 
interleukin-6 (NF-IL-6) which are essential for iNOS induction by IFN-γ (Kamijo et al., 
1994; Gao et al., 1994; Kim et al., 1997). Binding of IFN-γ to its receptor induces 
phosphorylation of STAT-1α via activation of the Janus family tyrosine kinases, JAK1 
and JAK2. The phosphorylated STAT-1 α assembles to form a homodimer, which then 
translocates into the nucleus and binds to a specific DNA sequence motif, termed the 
IFN-γ activation site (GAS). The activated STAT-1 α also binds to the GAS site of the 
IRF-1 promoter and induces IRF-1 (Seidel et al., 1995; Decker et al., 1991). 
Furthermore, the IRF-1 gene promoter has been described as containing a composite 
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GAS/κB element (Sims et al., 1993; Harada et al., 1994), and cooperative regulation of 
transcription by IRF-1 and NF-κB has been previously described (Garoufalis et al., 
1994; Neish et al., 1995).  
iNOS can be induced in almost every tissue and nucleated cell type. These include 
macrophages (Xie et al., 1992; Lowenstein et al., 1992), lymphocytes (Kirk et al., 
1990), hepatocytes (Adachi et al., 1993), chondrocytes (Palmer et al., 1993), glia and 
neurons (Koprowski et al., 1993), tumor cells (Sherman et al., 1993), pancreatic islets 
(Yamada et al., 1993), vascular smooth muscle cells (Perrella et al., 1994), platelets 
(Mehta et al., 1995), mesangial cells (Kunz et al., 1994) and renal tubular epithelium 
(Markewitz et al., 1993) (Table 3). The predominant mechanism underlying the 
induction of iNOS in these varied cell types is transcriptional regulation. Low basal 
rates of transcription are markedly enhanced by the treatment of cells with cytokines or 
LPS and maximal promoter activation occurs with synergistic combinations of 
proinflammatory cytokines such as TNF-α, IL-1β, IFN-γ and LPS. Functional 
characterization of the murine promoter of the 5’-flanking regions of the iNOS gene 
participate in the transcriptional response to the different exogenus stimuli (Xie et 
al.,1993; Xie et al., 1994; Lowenstein et al., 1993) (Figure 9).  
A proximal region of the promoter interacts with the NF-κB trans-acting factor. This 
DNA-binding complex resides in the cytosol of quiescent cells, bound to an inhibitory 
complex, IκB. Following the activation of cells by various agents, IκB dissociates and 
degrades and the DNA-binding complex migrate to the nucleus where it binds to cis-
regulatory regions of the iNOS promoter (Grilli et al., 1993; Xie et al., 1994). 
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p50/cRel and p50/RelA heterodimers represent at least a component of the trans-acting 
NF-κB complex that participates in transcriptional regulation (Xie et al.,1994). The NF-
κB binding site in the proximal region of the promoter has been shown to be critical for 
induction of the iNOS gene by LPS (Xie et al.,1993; Xie et al., 1994; Lowenstein et al., 
1993). Analysis of promoter/reporter constructs indicates that more distal regions of the 
promoter are involved in IFN-γ-stimulated changes in iNOS mRNA expression 
(Lowenstein et al., 1993; Xie et al., 1993). An IRF-1 cis-regulatory DNA region is 
implicated in this effect. Infact homozygous mice IRF-1 (-/-) do not exhibit an iNOS 
response following infection with cytokines or viruses (Kamijo et al., 1994). 
Thus, IFN-γ and LPS also exert effects on posttranscriptional regulation of the iNOS by 
increasing iNOS mRNA stability (Vodovotz et al., 1993; Weisz et al., 1994) which is 
stabilized also by cAMP elevating agents, such as dibutyryl cAMP and forskolin (Kunz 
et al., 1994). In constrat TGF-β destabilizes iNOS mRNA in various cell types (Perrella 
et al., 1994; Vodovotz et al., 1993), decreases the translation of iNOS and interferes 
with protein stability (Vodovotz et al., 1993).  
 
3.5 Role of NO in bowel disease  
A consistent finding in experimental and human bowel disease is the upregulation of 
iNOS and overproduction of NO (Rachmilewitz et al., 1995; Singer et al., 1996). 
Despite the role of iNOS-derived NO in bowel disease remains unclear, it is a particular 
interesting mediator that possesses both anti- and pro-inflammatory properties. The first 
ones are probably attributable to its ability to attenuate adhesion and recruitment of 
leukocytes in postcapillary venules exposed to different acute inflammatory stimuli. To 
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explaine antiadhesive properties of NO it has been proposed NO acts as a physiologic 
scavenger of reactive oxygen metabolites (Grisham et al., 1998) (Figure 10). 
The second ones are attributable to neovascularization by NO, which is known to be 
associated with bowel disease (Montrucchio et al., 1997). Infact the concentrations of 
citrulline, the co-product of NO synthase, were found to be higher in rectal biopsy 
specimens from patients with ulcerative colitis than in those from patients with 
quiescent disease or normal histology; incubation with inhibitors of NO synthases 
significantly reduced the concentration of citrulline in colonic biopsies, suggesting a 
role for iNOS (Middleton et al., 1993). Moreover it has been demonstrated that iNOS-
derived NO seems to be critical in mice colitis development. Genetic absence or 
pharmacological blockade of iNOS significantly attenuates the severity of colonic 
injury and inflammation in a model miming ulcerative colitis (Krieglstein et al., 2001). 
Finally it has been proposed that the high output production of NO from iNOS causes 
injury, perhaps through the generation of potent radicals such as peroxynitrite (Pryor 
and Squadrito, 1995).  
Although there is much evidence that peroxynitrite in buffer system can be extremely 
harmful to most cells, in vivo this evidence is forthcoming. It has been demonstrated 
that children with active CD have a gluten-induced NO production in small intestine 
reflected by urine levels of nitrate/nitrite and iNOS expression in the intestine 
(Holmgren Peterson et al., 1998). Moreover, recent studies reported that NO is 
produced in biopsy specimens cultured in vitro and that plays a role in the regulation of 
cytokine production, such as IL-1β (Beckett et al., 1999). Furthermore it has been 
shown that lamina propria cells of patients with active CD are positive to iNOS (Beckett 
et al., 1998). Finally, other studies ex vivo have correlated IRF-1 and STAT-1α 
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activation in small intestinal mucosa of celiac patients with the enhancement of iNOS 
gene expression (Mazzarella et al., 2003; Salvati et al., 2003). 
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4. Nuclear factor-κB (NF-κB) 
NF-κB is a transcription factor initially discovered and characterised by Sen and 
Baltimore in the kappa light chain of immunoglobulins in B cells (Sen and Baltimore, 
1986). Research over the last few years has revealed that NF-κΒ is an inducible and 
ubiquitously expressed transcription factor which plays an evolutionarily conserved and 
critical role in the triggering and coordination of inflammatory processes and in both 
innate and adaptive immune responses (Ghosh et al., 1998; Silverman and Maniatis, 
2001). NF-κB can be activated by a variety of pathogenic stimuli, including bacterial 
products and viral proteins, cytokines, growth factors, radiation, ischemia/reperfusion 
and oxidative stress. NF-κB activated, in turn, regulates the expression of wide variety 
of genes included those encoding cytokines, chemokines, adhesion molecules, acute 
phase proteins and inducible enzymes (Pahl, 1999). In addition, some of the chemokines 
and cytokines produced in response to NF-κB activation can stimulate the migration and 
maturation of lymphocytes. Furthermore, NF-κB is central for the overall immune 
response through its ability to activate genes coding for regulators of apoptosis and cell 
proliferation, that are critical for apoptotic processes (Karin and Lin, 2002). 
 
4.1 Structure and activation of nuclear factor-κB 
NF-κB exists in the cytoplasm of the majority of cells as homo or heterodimers of a 
family of structurally related proteins. Five proteins of the NF-κB family has been 
identified in mammalian cells: Rel (c-Rel), RelA (p65), RelB, NF-κB1 (p50 and its 
precursor p105) and NF-κB2 (p52 and its precursor p100) (Ghosh et al., 1998) (Figure 
11). The first three of these are produced as transcriptionally active proteins; the latter 
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are synthesised as large precursors, p105 and p100, respectively, that require proteolytic 
processing to produce the mature p50 and p52 proteins. The mechanisms by which the 
p105 and p100 precursor proteins are processed are not fully understood. What seems to 
be clear is that while p105 processing is constitutive, the processing of p100 is regulated 
(Karin and Ben-Neriah, 2000; Xiao et al., 2001). Each member of NF-κB/Rel family 
contains conserved a 300 amino acid long N-terminal region called Rel-homology 
domain (RHD) responsible for DNA-binding, dimerization and association with the IκB 
inhibitory proteins through the nuclear localisation signal (NLS) (Baldwin, 1996; Ghosh 
et al., 1998).  
Activation of NF-κΒ is regulated by its cytoplasmic inhibitor, IκΒ. IκΒ binds NF-κΒ 
and masks its NLS, thus retaining it in the cytoplasm (Baldwin, 1996). Like NF-κΒ, IκΒ 
is a member of a larger family of inhibitory molecules, including IκΒα, IκΒβ, IκΒε, 
IκΒγ and Bcl-3 in mammals (Figure 12) and the recently described inducible IκBζ 
(Yamazaki et al., 2001). The IκBs are characterized by the presence of multiple regions 
of homology known as the ankyrin-repeat motifs. The ankyrin repeats are regions of 
protein/protein interaction, and the specific interaction between ankyrin repeats and Rel-
homology domains appears to be a crucial, evolutionary conserved feature of the 
regulation of NF-κΒ protein. Each IκΒ differs in the number of ankyrin repeats, and this 
number appears to influence the specificity by which IκΒ pairs with Rel dimers (Ghosh 
and Karin, 2002).  
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The C-terminal region of p100 and p105 also contain similar ankyrin repeats and, prior 
to proteolytic processing, can function as IκB-like proteins, retaining NF-κB complex in 
the cytoplasm (Palombella et al., 1994; Baldwin, 1996). 
The best characterised IκΒs is IκΒα, mainly because it was the first member of this 
family to be cloned (Davis et al., 1991; Haskill et al., 1991). IκΒα is a 37 kDa protein 
that has a tripartite organization also seen in IκΒβ: an N-terminal domain that is 
phosphorylated in response to signal, a central ankyrin repeat domain and a C-terminal 
PEST domain that is involved in the basal turnover of the protein (Verma et al., 1995). 
Physiologically the defining characteristic of IκΒα is its ability to regulate rapid but 
transient induction of NF-κΒ activity, owing to the participation of IκΒα in an auto-
regulatory feedback loop; that is, the activation of NF-κΒ causes up-regulation of the 
transcription of IκΒα, which serves to shut off the signal (Brown et al., 1993; Scott et 
al., 1993). This up-regulation occurs owing to the presence of κΒ sites in the IκΒα 
promoter (de Martin et al., 1993; Le Bail et al., 1993). Thus IκΒα is thought to maintain 
the transient effect of inducing agents on the transcription of NF-κΒ responsive genes. 
The continuing presence of certain inducing agents (for example, LPS) however causes 
NF-κΒ to be maintained in the nucleus despite the up-regulation of IκΒα mRNA 
synthesis, and this persistent activation of NF-κΒ is regulated by IκΒβ (Thompson et 
al., 1995). IκBβ transcription is not regulated by NF-κB; therefore, the protein is slowly 
degraded following IL-1β and LPS stimulation and leads to persistent activation of NF-
κB (Weil et al., 1997; Johnson et al., 1996). The mechanism of persistent activation 
may involve a chaperone-like role of unphosphorylated or newly synthesized IκBβ that 
allows transport of NF-κB to the nucleus without being trapped by IκBα (Suyang et al., 
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1996; Ghosh et al., 1998). This pool of variably responding IκB molecules, with 
different kinetics of degradation, synthesis and affinity, may allow cells to activate NF-
κB differentially and, consequently, to regulate down-stream genes differentially in 
response to the wide array of stimulating agents (Ghosh et al., 1998). 
The activity of NF-κB is controlled by shuttling from the cytoplasm to the nucleus in 
response to cell stimulation. A large number of extracellular signals can trigger distinct 
signal transduction pathways, each of which culminates in the degradation of IκB 
proteins. These signal transduction pathways lead to the activation of the IκB kinase 
(IKK) and the subsequent phosphorylation of serine residues on the N-terminal region 
of IκB proteins (i.e. Ser32 and Ser36 for IκBα and Ser32 and Ser36 for IκBβ) (Karin and 
Ben-Neriah, 2000; Ben-Neriah, 2002). Phosphorylation determines the immediate 
recognition of IκB by the recently identified E3RSIκB/β-TrCP, an SKp1-Cullin-F-box 
(SCF)-type 3 ubiquitin ligase (Yaron et al., 1998; Laney and Hochstrasser, 1999; 
Maniatis, 1999), leading to its polyubiquitination (i.e. Lys21 and Lys22 for IκBα) and 
consequently rapid degradation by the ATP-dependent 26S proteasome (Ben-Neriah, 
2002; Karin and Ben-Neriah, 2000). Neither phosphorylation, nor ubiquitination alone 
is sufficient to dissociate the NF-κΒ-IκΒ complex, and hence free NF-κΒ is only 
released after degradation of IκΒ. The degradation of IκB unmasks the NLS of the NF-
κB leading to its nuclear translocation and binding to enhances or promoters of target 
genes (Figure 13). 
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IKK is a complex composed of three subunits: IKKα (IKK1), IKΚβ (IKK2) and 
IKKγ (also referred as NF-κB essential modulator, NEMO or IKK associated protein1, 
IKKAP1). IKKα and IKΚβ  are 85 and 87kDa proteins, respectively (Di Donato et al., 
1997; Mercurio et al., 1997; Zandi et al., 1997; Mégrier et al., 1997; Woronicz et al., 
1997). IKKα and IKΚβ are higly homologous proteins (50% sequence identity; >70% 
sequence similarity) and contain N-terminal protein kinase domains as well as leucine 
zipper (LZ) and helix-loop-helix (HLH) motifs. IKKγ is 48kDa protein (Rotwarf et al., 
1998; Yamaoka et al., 1998; Mercurio et al., 1999). Secondary-structure prediction 
algorithm indicates that IKKγ is predominantly helical with large stretcher of coiled-coil 
structure, including an LZ motif near the C terminus (Rotwarf et al., 1998) (Figure 14). 
IKKα and IKΚβ are the catalytic subunits of the complex. IKKγ has regulatory role and 
is required for activation of the complex by upstream signalling pathways (Ghosh and 
Karin, 2002). While IKΚβ is mostly required for the canonical NF-κB pathway, 
triggered by TNF-α, IL-1 or by products of bacterial and viral infections (i.e. LPS) (Li 
Q et al., 1999; Delhase et al., 1999; Li Z et al., 1999), IKKα is involved in a non-
canonical NF-κB pathway, stimulated by only a few members of the TNF family, such 
as lymphotoxin β (LT β), that regulates the RelB/p52 dimer (Solan et al., 2002; 
Senftleben et al., 2001a) (Figure 15). Whereas the canonical NF-κB pathway, which is 
based on IκB degradation, is essential for innate immunity (Senftleben et al., 2001b), 
the second pathway, which is based on NF-κB2 processing, is mostly involved in 
lymphoid organ development and adaptive immunity (Senftleben et al., 2001a).  
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Once in the nucleus, NF-κB dimers are subject to further regulation mainly through 
phosphorylation of the Rel proteins, which is required for full induction of NF-κB target 
genes (Zhong et al., 1997; Sizemore et al., 1999). Several signalling pathways, which 
induce the phosphatidyl inositol 3-kinase (PI 3-K)/Akt pathway, are thought to be 
involved in this process (Madrid et al., 2001). 
                   
4.2 NF-κB and inflammation  
NF-κB plays a crucial role in many inflammatory diseases, such as rheumatoid arthritis 
(RA), asthma and inflammatory bowel disease. It has also been implicated in other 
diseases such as atherosclerosis and Alzheimer’s disease (Baldwin, 2001). In cells 
associated with these diseases, NF-κB has been found with aberrant, constitutively 
nuclear localization and enhanced transcriptional activity. It is probable that the role of 
NF-κB in inflammatory diseases results from defect in the regulatory mechanisms 
controlling its activation. Experimental evidence suggests a pivotal role for NF-κB both 
at the stage of initiation and perpetuation of chronic inflammation, because an important 
aspect of the significance of NF-κB in these processes stems from it both being 
activated by and inducing the expression of inflammatory mediators. 
CD4+ T cells are considered a trigger of immune inflammation. They become activated 
when the T-cell receptor (TCR) recognizes fragments of auto-antigens presented by the 
MHC class II molecules of APCs. Another signal required for T-cell activation is 
provided by the interaction of CD28 with its ligands, the co-stimulatory molecules 
CD80 and CD86 that are expressed by APCs. The engagement of TCR and CD28 
activates NF-κB in T cells, which is required for the induction of NF-κB-dependent 
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genes controlling activation and proliferation of T cells, such as interleukin-2 (IL-2), IL-
2 receptor (IL-2R) and IFN-γ (Ghosh et al., 1998; Schulze-Osthoff et al., 1997; 
Sheppard et al., 1999; Gerondakis et al., 1998). 
T cells that are found in inflammatory lesions express on their surface CD40 ligand 
(CD40L) (Grewal and Flavell, 1998; Stout and Suttles, 1996) and TRANCE (TNF-
related activation-induced cytokine also known as RANKL, receptor activator of NF-κB 
ligand) (Anderson et al., 1997; Wong et al., 1999), the molecules of the TNF 
superfamily. Interactions of CD40L and TRANCE/RANKL with the APC receptors 
CD40 and RANK induce NF-κB activation, promote survival of APC cells and augment 
their ability to stimulate T-cell proliferation and activation, possibly by upregulating the 
expression of NF-κB-dependent molecules MHC class II, CD80 and CD86 (Li J et al., 
1999; Verhasselt et al., 1999). Thus, NF-κB appears to be an important mediator of 
antigen-induced T cell activation. 
Activated CD4+ T helper (Th) cells can differentiate into the subsets whose cytokine 
profile is restricted to Th1 (IL-2 and IFN-γ-dominant) or Th2 (IL-4-, IL-5-dominant) 
patterns. Th1 cells, that mediate cellular immunity and activate macrophages, are 
considered pro-inflammatory, whereas Th2 cells, that potentiate antiparasite and 
humoral immunity and down-regulate macrophage activation, are considered anti-
inflammatory. Suppression of NF-κB pathway in T cells promotes Th2 development 
(Aronica et al., 1999), whereas NF-κB activation promotes type 1 responses, 
presumably through the induction of NF-κB-dependent Th1 cytokines IL-2, IFN-γ and 
IL-12 (Li B et al., 2000). 
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Secreted products of activated T cells and direct cell-cell contacts cause activation of 
macrophages, fibroblast and endothelial cells. NF-κB controls the expression of the 
cytokines IL-1β and TNF-α, which are essential mediators of chronic inflammation and 
implicated in leukocytosis, hyperplasia and tissue breakdown (Hiscott et al., 1993; 
Shakhov et al., 1990). Because both IL-1β and TNF-α are also potent inducers of NF-
κB activation, an interdependence of persistent NF-κB activation and sustained levels of 
IL-1β and TNF-α is indicated (Miagkov et al., 1998; Tomita et al., 1999). Elevated 
levels of other NF-κB-dependent gene products, including IL-6 and IL-15, the adhesion 
molecules E-selectin, vascular cellular adhesion molecule-1 (VCAM-1) and 
intercellular adhesion molecule-1 (ICAM-1), and the chemokines IL-8, macrophage 
chemotactic protein-1 (MCP-1) and MIP-1α, promote recruitment of inflammatory cells 
and their activation (Libermann and Baltimore, 1990; Azimi et al., 1998; Iademarco et 
al., 1992; van de Stolpe et al., 1994; Kunsch and Rosen, 1993; Ueda et al., 1994; Grove 
and Plumb, 1993; Pahl, 1999). 
Activation of non-immune cells, particularly fibroblasts, promotes tissue remodelling in 
inflammatory lesions. In RA, activated fibroblast-like synoviocytes secrete large 
amounts of matrix proteinases, including NF-κB-dependent metalloproteinases (MMPs) 
MMP-1, MMP-3 and MMP-9 (Bond et al., 1998; Bond et al., 1999). Another 
mechanism of tissue remodelling/destruction is mediated by the induction of NF-κB-
dependent genes encoding inducible forms of cyclooxygenase (COX-2) and iNOS, 
enzymes catalyzing the synthesis of pro-inflammatory prostaglandins, NO and nitric 
oxide metabolites, respectively (Yamamoto et al., 1995; Xie et al., 1996). Activation of 
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NF-κB in fibroblasts also promotes neovascularization of inflammatory lesions through 
induction of vascular endothelial growth factor (VEGF) (Chilov et al., 1997).  
 
4.2.1 NF-κB in inflammatory bowel disease 
Recent studies have shown increased production of pro-inflammatory cytokines in 
inflammatory bowel disease (MacDonald et al., 1990). NF-κB is thought to be an 
important factor in pathophysiology of intestinal inflammation in inflammatory bowel 
disease. However the pivotal elements in  the regulation of the increased inflammatory 
activity remain unclear. An important candidate involved in the regulation of 
inflammation gene transcription is NF-κB. Infact many of the inflammatory cytokine 
genes include NF-κB binding sites, and most have been shown to be regulated by this 
factor (Baldwin, 1996). Most interestingly NF-κB dimers containing p65 appear to have 
profound proinflammatory activity, whereas the p50 homodimer is either inactive or 
may be even involved in blocking NF-κB sites in some inflammation gene promoters 
against binding of p65 dimers (Ledebur and Parks, 1995). Recent studies suggest that 
activation of NF-κB involving the p65 subunit may be a key event in 
trinitrobenzenesulphonic acid (TNBS)/ethanol colitis (Neurath et al., 1996). Although 
not shown in vivo, a role for NF-κB/p65 has been suggested in Chron’s disease. Infact 
nuclear extracts from lamina propria of these patients contained substantially higher 
levels of NF-κB/p65 (MacDonald et al., 1990) and biopsy specimens as well as isolated 
lamina propria mononuclear cells from patients with active inflammatory bowel disease 
show enhanced activation of  NF-κB. Therefore when activation of NF-κB involves the 
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p65 subunit, may contribute to the enhanced expression of inflammation genes observed 
in inflammatory bowel disease (Schreiber et al., 1998).  
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5. Signal Transducer and Activator of Transcription 1-α (STAT-1α)  
5.1 Structure and activation of Signal Transducers and Activators of Transcription 
(STATs) 
Cytokines regulate numerous aspects of hematopoiesis and immune response. They 
mediate their responses through activation of the Jak/STAT signaling pathway. STATs 
comprise a family of seven structurally and functionally related proteins: STAT-1, 
STAT-2, STAT-3, STAT-4, STAT-5a, STAT-5b and STAT-6. Janus kinases (Jak) 
represent a family of four non-receptor tyrosine kinases, Jak1, Jak2, Jak3 and Tyk2. 
These kinases selectively phosphorylate STATs, leading to their activation. Once 
activated, STAT then play a critical role in regulating innate and acquired host immune 
responses. Dysregulation of at least two STAT signaling cascades is associated with 
cellular transformation. STATs transduce signals for the large hematopoietin subfamily 
of cytokines and the conserved family of the receptors they bind. This includes the IFN 
family (IFN-α,β and γ; IL-10, IL19, IL-20, IL-22), the gp130 family (IL-6, IL-11, 
GCSF, Leptin), the γC family (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) and the single chain 
family (Epo, GH, PRL, Tpo) of the receptors (Schindler and Strehlow, 2000) (Figure 
16). STATs can also be activated by receptor tyrosine kinases; also several members of 
the G-protein-coupled receptors, a primitive family, have also been shown to signal 
through STATs (Leonard and O’Shea, 1998). Signaling through the Jak/STAT pathway 
is initiated when cytokine binds to its corresponding receptor; this leads to a 
conformational change in the cytoplasmic portion of the receptor, initiating activation of 
receptor associated members of the Jak family of kinases. 
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The Jaks, in turn, mediate phosphorylation at the specific receptor tyrosine residues, 
which then serve as docking sites for STATs and other signaling molecules. Once 
recruited to the receptor, STATs also become phosphorylated by Jaks, on a single 
tyrosine residue. Activated STATs dissociate from the receptor, dimerize and 
translocate to the nucleus binding to members of the gamma activated site (GAS) family 
of enhancers. 
Upon ligand stimulation, cytokines receptors undergo the conformational changes that 
bring Jaks, which are constituvely associated with a proline-rich membrane proximal 
domain of these receptors, into proximity of each other, to mediate signal transduction. 
The four members of Jak family (Jak1, Jak2, Jak3 and Tyk2) are over 1000 amino acids 
in lenght, ranging in molecular weight from 120 to 130 kDa. Jak1, Jak2 and Tyk2 are 
expressed ubiquitously, whereas the expression of Jak3 is restricted to cells of the 
myeloid and lymphoid lineages (Leonard and O’Shea, 1998). Comparison of Jak 
sequences reveals seven regions of high homology, JH1-JH7. Altough the biological 
activity of each of these regions has not been fully elucidated, several domains are well 
characterized (Ihle, 2001). JH1 has been shown to encode the kinase while JH2 
represents a pseudokinase domain, which appears to be required for JH1 catalytic 
activity (Yeh,  2000). The amino-terminal JAK homology domains, JH3-JH7, have been 
implicated in receptor association altough the role of JH7 region in this interaction has 
not been confirmed. 
The seven STAT proteins identified in mammals range in size from 750 and 850 amino 
acids. Both, the  cromosomal distribution of these STATs, as well as the identification 
of STATs in more primitive eukaryotes, suggest that this family arose from a single 
primordial gene. Duplications of this locus appear to reflect an increasing need for cell-
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to-cell communication as eukaryotes became more complex. Consistent with this 
evolutinary pattern, STATs share structurally and functionally conserved domains. This 
includes the amino-terminal domain, the coiled-coil domain, the DNA binding domain, 
the linker domain and the SH2/tyrosine activation domain. In contrast the carboxy-
terminus domain is quite divergent and contributes to STAT specificity. Despite the fact 
that over 50 members of the hematopoietin family transduce signals through a more 
limited number of STATs, significant specificity is achieved. This is largely because the 
receptors that transduce signals for these cytokines can be placed into five structurally 
and functionally related subfamilies, each of which tend to transduce signals through a 
single STAT. Further specificity can be attributed both to tissue specific patterns of 
expression and the activation of additional signaling pathways by these receptors. 
Structural studies of several hematopoietin receptors from the cytokine family indicate 
that ligand binding promotes the dimerization of receptors into an active conformation 
(Wells, 1996). In each case of activation is believed to lead to close approximation of 
cytoplasmic receptor tails, enabling the transphosphorylation of the receptor-associated 
Jaks. Activated Jaks then phosphorylate specific tyrosine motifs present in the receptor 
endodomains, which in turn mediate the recruitment of STATs to their appropriate 
receptor. This entails the ability of a STAT domain to recognize a phosphotyrosine 
residue and 4-5 carboxy-proximal amino acids, known as the receptor STAT 
recruitment motif. In unstimulated cells STATs predominantly localize to the cytoplasm 
and upon stimulation rapidly translocate to the nucleus and induce gene expression. 
After termination of the signal, STATs translocate back to the cytoplasm (Figure 17).  
This regulated mobilization of STATs is an essential step for signaling and is mediated 
by the nuclear pore complex (NPC) (Doye and Hurt, 1997). Like all molecules larger 
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than 60 kDa STATs are transported across the NPC in an active bidirectional process 
that is energy and activation dependent. 
 
5.2 IFN-γ receptor  
IFN-γ, like IFN-α plays a key role in innate and acquired host immune responses (Bach, 
1997). It can inhibit viral and cellular proliferation and regulate apoptosis. Unlike IFN-
α, IFN-γ function is required for host defenses against several intracellular pathogens. 
IFN-γ is predominantly produced by activated T lymphocytes and natural killer (NK) 
cells. However its receptor is expressed on most cells. Cellular responses following 
IFN-γ stimulation are mediated through the recruitment of STAT-1 to a single STAT-1 
binding site and its subsequent activation by Jak1/Jak2 (Greenlund, 1994). Both IFN-γ 
receptors chains participate in signal transduction as demonstrated by targeted 
disruption of the two chains (Lu, 1998). Investigations of IFN responses has identified 
two different transcriptional enhancers within the promoter elements of STAT target 
genes (Schindler and Brutsaert, 1999). IFN-γ, through STAT-1 homodimers, binds to a 
distinct response element,  known as GAS (Decker, 1997). This palindromic element 
has a consensus sequence of TTTCCNGGAAA.  
Similar responsive elements have been identified in the promoters of other STAT-
induced genes. Biochemical studies have determined that TTCN2-4GAA consensus 
defines the optimal binding site for all STATs, with an exception of STAT-2, which 
appears to be defective in DNA binding. This provides an opportunity for most STAT 
homodimers to exhibit unique DNA binding preferences. In part this is determined by 
spacing between palindromic half sites (Ehret, 2001).  
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Recent studies indicate the ability of STATs to bind cooperatively to tandem GAS 
elements also contributes to DNA binding specificity. Moreover these tandem sites 
often include nonconsesus GAS elements (Ehret, 2001) 
 
5.3 Genetics and functions of STATs family 
Gene-targeting studies indicate that STATs largely evolved to mediate host response to 
stress in mammals (Ihle, 2001). Moreover, these studies highlighted a remarkable level 
of specificity in STAT function: for example STAT-1 and STAT-2 predominately 
transduce signals for IFNs, likewise STAT-4 and STAT-6 play an important role in the 
polarization of native T cells into Th1 and Th2 cells, respectively. However STAT-3 
and STAT-5, which are activated by more cytokines, are more pleiotropic in their 
function so they appear to be more closely realted to the STATs found in lower 
eukaryotes. 
STATs are well conserved during eukaryotic evolution and may encode the primordial 
SH2 domain. Studies in Drosophila demonstrate how the Jak/STAT pathway is 
important for many functions, like hematopoiesis, sexual identity and embryo 
segmentation (Zeidler, 2000). 
In mammals the seven STATs are segregated to three clusters each of which represents 
a tandem duplication. STAT-1 and STAT-4 map to chromosome 1, STAT-2 and STAT-
6 cosegregate on chromosome 10 while STAT-3 and STAT-5 are located on 
chromosome 11 although the STAT-5 has undergone an additional duplication more 
recently in evolutionary history (Copeland, 1995). According to this, analysis of STAT-
3 and STAT-5 gene structure suggests that these two STATs may have been the first 
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mammalian STATs (Miyoshi, 2001). This may also account for the relative functional 
pleiotropy of these two STATs. 
 
5.4 STAT-1 
Investigations into IFNs signalling pathways led to the discovery of STAT-1. IFN-γ 
activates STAT-1 homodimers, which initiate transcription of GAS-driven genes. This 
has been confirmed by the generation of STAT-1 knockout mouse (Durbin, 1996). 
Infact these mice were defective in IFN dependent immune response to both viral and 
microbial agents because they failed to induce transcription of STAT-1 target genes. 
Over the last several years STAT-1 null mice have been exploited to demonstrate the 
wide role IFN-γ plays in regulating innate and acquired immunity (Schindler and 
Strehlow, 2000). Recent studies underline the role IFN-γ plays in protecting mice from 
chemically induced and spontaneous tumors. STAT-1 and IFN-γ deficient animals 
develop these tumours more rapidly and frequently than wild-type mice. These 
observations provide compelling evidence for an IFN-γ/STAT-1 dependent tumor 
immune surveillance system in immune competent host (Shankaran, 2001). Moreover, 
studies in STAT-1 null mice have also provided evidence for non-immune role for 
STAT-1. For example many studies have suggested that STAT-1 affects apoptosis 
through the regulation of caspase 1, 2 and 3 (Chin, 1997; Huang et al., 2000) and that 
inactive STAT-1 prevents cell apoptosis (Kumar, 1997). The identification of low levels 
of STAT-1 in the nucleus of unstimulated cells suggests that STAT-1 might cooperate 
with other transcriptional factors to regulate the basal expression of genes that regulate 
apoptosis (Schindler and Strehlow, 2000). 
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5.5 Regulation of the Jak/STAT signalling pathway 
Numerous regulatory layers exist to modulate this signalling pathway. The effects of 
these regulatory processes, which can be both negative and positive, determine the rate 
at which STAT signals are transduced. 
Recent studies determined that STAT signals are downregulated at several points 
(Figure 18). A common mechanism of downregulation involves receptors and entails 
receptor endocytosis (Dittrich, 1996). Also ubiquitin-proteasome dependent degradation 
may play a role in lowering cytokine signalling: proteasome inhibitors have been found 
to impede the degradation of both STAT-1 and IFN-γ receptors (Kim and Maniatis, 
1996) and to prolong Jak activity (Yu and Burakoff, 1997). 
Since Jak activation depends on tyrosine phosphorylation phosphatases have been found 
to negatively regulate its activity. STAT activation is directly antagonized by the 
suppressor of cytokine signalling (SOCS), a family of STAT target genes that 
estabilishes an important and classic feedback loop (Kile et al., 2001). STAT activity 
can also be negatively regulated through direct modifications, for example 
dephosphorylation and generation of carboxy-terminally truncated isoforms (Mowen et 
al., 2001). Reporter gene studies have determined that serine phosphorylation enhances 
transcriptional activity of STATs, except STAT-5 and STAT-6 (Kovarik, 2001; 
Visconti, 2000; Yamashita, 1998). Numerous studies have identified a substantial 
interaction between STATs and other transcription factors. Analysis of STAT 
dependent promoters provided functional and biochemical evidence for the interaction 
with other transcription factors: STAT-1 was found to interact with NF-κB, Sp1, USF-1 
and the glucocorticoid receptor (Look, 1995; Ohmori, 1997; Aittomaki, 2000).  
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Other studies have demonstrated the association between STATs and proteins that 
facilitate transcription through chromatin modification (Horvath and Mehta, 2000). 
Finally yeast two hybrid screens have identified non-nuclear proteins that associate with 
STATs (Collum, 2000). 
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6. Interferon Regulatory Factors (IRF) 
6.1 Structure and activation of Interferon Regulatory Factors (IRFs) 
IFNs are a heterogeneous family of multifunctional cytokines, which were originally 
identified as proteins responsible for the induction of cellular resistance to viral 
infections. Subsequently, much evidence has accumulated with their regard to their 
roles in cell growth, differentiation and immunomodulation (Vilcek, 1996). Studies of  
IFN-α and IFN-β gene regulation have identified a factor termed IRF-1 as a protein that 
binds to the virus-inducible elements of the human IFN-β gene (Miyamoto, 1988). 
Subsequently it has been identified also IRF-2 by cross-hybridization with cDNA 
(Harada, 1989). Mutational analysis of  IRF-1 and IRF-2 revealed that DNA-binding 
activity resides in the amino-terminal region, with some highly conserved amino acids, 
particularly five tryptophan repeats. After the cloning of IRF-1 and IRF-2, several 
factors which share a significant homology with IRF-1 and IRF-2 in their amino-
terminal region have been identified. Notably these factors conserved the five 
trypthophan repeats. These factors now constitute a family of transcription factors, 
which includes IRF-3, IRF-4 (Pip, LSIRS, ICSAT, MUM1), IRF-5, IRF-6, IRF-7, IRF-
8 (ICSBP) and IRF-9 (p48, ISGF3γ) (Taniguchi, 2001). These members are 
ubiquitously expressed, except for IRF-4 and IRF-8 whose expression is restricted to 
hematopietic cells. The consesus IRF-1/IRF-2 binding motif, termed IRF Element (IRF-
E) was determine to be G(A)AAAC/TGGAAAG/TC/C by the random oligosection method 
(Tanaka, 1993). As the DNA binding domain of these factors is highly conserved, IRF 
members recognize similar DNA sequences (Taniguchi, 2001). In contrast recent gene 
targeting for IRF members clearly demonstrate their specialized role in the regulation of 
target gene expression and host defense. 
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6.2 Expression of IRF-1 
IRF-1 was isolated by virtue of its affinity to specific DNA sequences in the IFN-β 
promoter that mediates virus responsiveness (Fujyta, 1988; Miyamoto, 1988). With the 
exception of early embrional cells, IRF-1 mRNA is expressed at a low basal level in all 
cell types examined. IRF-1 mRNA levels accumulate in response to IFNs, double-
stranded RNA (dsRNA), cytokines and some hormones. IFN-γ is the strongest IRF-1 
inducer known, altough some combinations, such as IFN-γ and tumor necrosis factor 
alpha (TNF-α), induce even higher levels of IRF-1 mRNA (Ohmori et al., 1997). On 
the other hand, other cytokines can antagonize IRF-1 induction; for example, interleukin 
4 (IL-4) reduces IFN-γ-stimulated IRF-1 transcription (Coccia et al., 2000). As the IRF-
1 protein has a short half life of 30 min, IRF-1 mRNA levels most probably correlate 
with IRF-1 protein abundance (Watanabe et al., 1991). IRF-1 mRNA levels are cell-
cycle regulated (Harada et al., 1993). The levels are elevated in serum-starved cells in 
G0 and successively lowered after serum-induced growth. IRF-1 mRNA levels increase 
before and during S phase. This is indicative of a short half-life of IRF-1 mRNA that 
permits such rapid changes. Altough it is not known what mechanism control cell cycle-
dependent accunulation of IRF-1 mRNA levels, most inducers lead to activation of IRF-
1 gene transcription. Key promoter elements are IFN-γ-activated sequences (GAS) and 
binding sites for NF-κB. These sites mediate transcription induction on binding STAT-1 
and NF-κB respectively (Harada, 1994; Durbin, 1996) (Figure 19). Interestingly, IRF-1 
can also activate IRF-2 promoter. IRF-2 inhibits the transcription of IRF-1-activated 
genes. Because IRF-2 accumulation is delayed relative to IRF-1 due to a much longer 
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half-life, IRF-2 acts as a negative feed-back mechanism to limit postinduction IRF-1 
activity (Harada et al., 1994). 
 
6.3 Structure and activities of IRF-1 
The most crucial activity of IRF-1 is its ability to activate transcription from specific 
promoters. Inactivation of its DNA-binding capacity or deletion of the amino acid 
sequences required for transcriptional activation eliminates all phenotypic response to 
IRF-1 overexpression (Kirchhoff, 1993). IRF-1 is a typical modular protein (Schaper, 
1998). Distinct protein domains have been characterized that mediate transcriptional 
activation, DNA binding, nuclear translocation and heterodimerization with IFN 
consesus sequence binding protein (ICSBP). The N-terminal 125 amino acids encoding 
the DNA-binding domain (DBD) are structurally and functionally conserved among the 
IRF family. DBD is characterized by a winged type helix-loop-helix motif with five 
tryptophan repeats (Uegaki, 1995). IRF-1 binding sites contain a direct hexameric 
nucleotide repeat; IRF-1 may bind DNA either as a monomer or as a dimer. The dimer 
could interact with opposing sites of the DNA double helix. IRF-1 is constituvely 
localized in the nucleus (Pine et al., 1990). The transcription factor contains two 
consesus signal sequences (NLS). It is a weak transcriptional activator: two activator 
fragments located between amino acids 185 and 256 function in an additive manner 
(Schaper, 1998).  
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A C-terminal fragment of IRF-1, which has no activator function by itself, acts as a 
strong enhancer of these activator sequences. A novel type of repression domain in the 
N-terminal 60 amino acids of IRF-1 that strongly inhibits its transcriptional activity and 
is conserved in some but not all IRF family members was identified (Kirchhoff et al., 
2000). These antagonistic acting domains may contribute to a balanced overall IRF-1 
activity. This is regulated by different means: primarily it is regulated at the 
transcriptional level; since IRF-1 is serine/threonine phosphorylated at multiple sites the 
role of this phosphorylation was examined but this kind of regulation can neither be 
verified nor excluded (Lin, 1999). IRF-2 and IRF-8 are functional antagonists of IRF-1. 
The first one represses the IRF-1 transactivation of certain promoters. This is thought to 
be due to competition of both factors for the same DNA-binding sites (Yamamoto et al., 
1994). The second one has been shown to repress IFN and IRF-1 mediated activation of 
IFN-stimulated response element (ISRE)-driven genes (Weisz et al., 1994). 
IRF-1 interacts also with other transcription factors. The interaction with NF-κB is 
crucial for the induction of several promoters (Thanos and Maniatis, 1992). One such 
example is the iNOS promoter. Induction of iNOS is relevant for production of NO as 
defense against bacterial infections and for elimination of tumor cells. Bacterial 
compounds, such as lipopolysaccharides (LPS), induce NF-κB and hypoxia in tumor 
activates hypoxia-induced factor-1 (HIF-1) (Tendler et al. 2001). A combined action of 
IFN-γ with either of the coinducers leads to iNOS promoter activation. IRF-1 also 
cooperates with the tumor suppressor p53 (Tanaka et al., 1996). 
In a wide variety of unrelated cell types from different mammalian species, such as 
human and mouse, ectopic overexpression of IRF-1 leads to growth inhibition (Coccia 
et al. 1999). A first indication of these antiproliferative effects was the low number of 
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stable transfectants that were obtained when cells were transfected with DNA encoding 
IRF-1 and none of these transfectants efficiently expressed IRF-1 (Kirchhoff et al., 
1993). To investigate the relationship of IRF-1 activities and cell growth, recombinant 
IRF-1 was expressed from a tetracycline-regulated promoter. Alternatively, a fusion 
protein of IRF-1 with the hormone-binding domain of the human estrogen receptor was 
expressed, such that the DNA-binding specificity of IRF-1 was preserved and the 
transcriptional activator function of the fusion protein was dependent on estrogen. The 
antiproliferative effects of these constructs and the inactivity of DBD or DNA activation 
domain mutants showed that the growth inhibition is due to the potential of IRF-1 to 
stimulate transcription of antiproliferative acting agents (Kirchhoff et al., 1993; Nguyen 
et al., 1997). Physiologically, IRF-1 is transiently induced. Infact the growth inhibitory 
effect of IRF-1 extends significantly beyond the IRF-1 activation period. Activation of 
the IRF-1-estrogen-receptor fusion protein for a day or less is sufficient to mantain a 
reduced growth rate for several days in the absence of cell death. However, the cells 
recover and resume normal growth subsequently, demonstrating that IRF-1-induced 
growth arrest is reversible (Geserick et al., 2000). IRF-1 might cause cell growth 
inhibition by inducing IFN-β gene expression or by other secreted factors. 
The role of IRF-1 as tumor suppressor was first revealed by its ability to reverse IRF-2-
induced transformation of NIH-3T3 cells and tumor formation in nude mice (Harada et 
al., 1993). IRF-1 can prevent anchorage-independent growth of cells transformed by 
various oncogenes, such as c-myc and c-fos (Tanaka et al., 1994). In addition, IRF-1 
expression reverses the transformed phenotype of tumor cell lines and of cells 
transformed by one or more oncogenes, indicating that IRF-1 can act as general 
suppressor of transformation (Tanaka et al., 1994). It has been shown that inactivation 
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of IRF-1 is implicated in the development and progression of human cancer, such as 
medulloblastoma and glioblastoma (Park et al., 1998). The mechanisms by which IRF-1 
exerts its tumor suppressive activities are not well understood. Several IRF-1-induced 
genes may be involved whose induction leads to proliferation inhibition, induction of 
apoptosis, stimulation of the immune response and reversion of transformed phenotype. 
In general IRF-1 does not promote cell death. Under certain conditions, however, it 
promotes apoptosis. DNA damage-induced apoptosis of mitogen-activated T 
lymphocytes is dependent on IRF-1 (Tamura et al., 1995). It has been shown that the 
induction of caspase-1 by IRF-1 is an essential component of apoptosis induction. 
Furthermore, IRF-1 can act as a mediator of cytokine-induced apoptosis. One 
underlying mechanism seems to be caspase-3 activation by IFN-γ. Caspase inhibition 
cannot prevent cell death but directs cells to undergo necrosis instead of apoptosis. 
Consequently, IRF-1 induction appears to be an important signaling event in initiation 
of apoptosis by IFN-γ. 
Besides its function as apoptosis promoter, a role as apoptosis suppressor has been 
ascribed to IRF-1 (Chapman et al., 2000). Moreover IRF-1 regulates the expression of a 
number of genes whose products play a central role in both innate and adaptative 
immunity, suggesting that IRF-1 may provide a link between the two systems. 
IRF-1 induces the transcription of many genes involved in first reaction to viral 
invasion, such as PKR (Kirchhoff et al., 1995). IRF-1 regulates the expression of iNOS 
in macrophages (Kamijo et al., 1994). iNOS catalyzes the reaction of short-lived 
volatile gas NO, which is one of the principal mechanisms of macrophage cytotoxiciyìty 
against tumor cells, bacteria, protozoa, helmints and fungi (Nathan, 1991). iNOS gene 
transcription is induced by both IFN-γ and LPS (Ding et al., 1990). IRF-1 binding sites 
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were identified in the promoter of iNOS gene and IRF-1 is essential for iNOS 
induction2, demonstrating that IRF-1 is involved in antibacterial response. IRF-1 
overexpression induces the transcription of IFN-α and IFN-β. Besides the involvement 
in antiviral effects, IFN-α and IFN-β have a number of other immune stimulatory 
effects on macrophages and T cells (Bogdan et al., 2000). Also IRF-1 influences 
development and function of natural killer (NK) cells (Taki et al., 1997). Finally, 
overexpression of IRF-1 by tumor cells leads to increased MHC class II and IFN-β gene 
expresssion (Kroger et al., 2001). IRF-1 overexpression suppresses tumor formation in 
syngenic mice and subsequently protects mice against rechallenge with related tumor 
cells that are not overexpressing IRF-1. This indicates that IRF-1 plays a role not only 
in antagonism of tumor cell growth but also in stimulating an immune respone against 
tumor cells. 
 
 
 
 
 
 
 
  
                                                 
2 IRF-1 binding site on iNOS promoter is showed in Figure 9 and descripted in chapter 3.4 at 
page 17  
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7. Materials and methods 
7.1 Gliadin and Zein digest 
Pure bread wheat (Triticum Aestivum, var. San Pastore) was kindly supplied by the 
“Istituto Sperimentale per la Cerealicoltura”, Rome, Italy. Peptic-tryptic digest of 
gliadin (Pt-G), purified prolamin fraction, were prepared following a two-step procedure 
as previously described (De Ritis et al., 1979). Gliadin (100 g) pool was digested in 1 
liter of HCl 0.2 M (pH 1.8) with 2 g of purified pepsin at 37 °C for 2 h. The resultant 
peptic digest was further digested by addition of 2 g of purified trypsin after pH 
adjustment to 8.0 with NaOH 2 M. The reaction mixture was vigorously stirred at 37 °C 
for 4 h at pH 8.0. During the entire digestion procedure, the pH was checked 
periodically and when needed adjusted with HCl or NaOH. At the end of the whole 
digestion period, the digest was submitted to gel filtration and the peptide fractions 
eluted after cytocrome c were collected, freeze-dried and stored at –20 °C. Zein (Z) 
from maize (Sigma, Milan, Italy), was extracted from commercial preparations with 70 
% (v/v) ethanol and freeze-dried. Z (1 g) was dissolved in 10 ml of HCl 0.1M. Pepsin 
(20 mg) was added and after digestion for 4 h at 37 °C, pH was adjusted to 8.0 by  
NaOH 5.0M. The zein was then further digested with 20 mg trypsin at 37°C for 4 h. 
Inactivation of trypsin was achieved by heating at 90 °C for 5 min. Insoluble material 
was removed by centrifugation at 10,000 g for 30 min. The peptic-tryptic digest of zein 
(Pt-Z) was finally freeze-dried and stored at -20 °C. 
 
7.2 Patients  
Biopsy specimens from the distal duodenum were obtained by upper gastrointestinal 
endoscopy from 6 children with coeliac disease on a normal gluten containing diet 
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(untreated) and 7 with celiac disease following gluten-free diet from almost 3 years 
(treated). Histological examination was performed on half specimen, while half sample-
tissue was immediately frozen in liquid nitrogen and then tested. Diagnosis of coeliac 
disease was performed in all patients for anti-endomisial antibodies positivity (EMA) 
and typical mucosal lesions with crypt hyperplasia, villous atrophy, increased number of 
intraepithelial lymphocytes. Control pediatric patients (n = 5) underwent upper 
gastrointestinal endoscopy for gastrointestinal symptoms, but were EMA negative and 
their duodenal histology was normal. This study received ethical approval from local 
committee (University Federico II, Naples, Italy). 
 
7.2.1 Organ culture 
The mucosal specimens from other untreated children (n = 4) were cultured as 
previously described (Picarelli et al., 1996) were incubated with medium alone at 
different time points (0, 2, 4, 6, 12 and 24 h). After 24 h incubation with medium alone 
the specimens were incubated for 2, 4 and 6 h with peptic-tryptic digest of gliadin (Pt-
G; 1 mg/ml). Pt-G, purified prolamin fraction, was prepared as previously described (De 
Ritis et al., 1979). The dishes were placed in a tight container with 95% O2/ 5% CO2 at 
37 °C, at 1 bar. Biopsies were snap-frozen and stored at –80 °C until used. 
 
7.2.2 Cytosolic and nuclear extracts from biopsy specimens 
Cytosolic and nuclear extracts of biopsy specimens were prepared as previously 
described with some modification (D’Acquisto et al., 2001). Briefly, each biopsy 
specimen was frozen in liquid nitrogen, immediately suspended in 150 µl of ice-cold 
hypotonic lysis buffer (10 mM Hepes, 10 mM KCl, 0.5 mM 
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phenylmethylsulphonyfluoride, 1.5 µg/ml soybean trypsin inhibitor, 7 µg/ml pepstatin 
A, 5 µg/ml leupeptin, 0.1 mM benzamidine, 0.5 mM dithiothreitol) and homogenized 
using a glass homogenizer and a teflon pestle. The homogenates were chilled on ice for 
15 min and then vigorously shaken for another 15 min in the presence of 20 µl of 10% 
Nonidet P-40. The nuclear fraction was precipitated by centrifugation at 1500 g for 5 
min, the supernatant containing the cytosolic fraction was removed and stored at –80 
°C. The nuclear pellet was resuspended in 100 µl of high salt extraction buffer (20 mM 
Hepes pH 7.9, 10 mM NaCl, 0.2 mM EDTA, 25% v/v glycerol, 0.5 mM 
phenylmethylsulphonyfluoride, 1.5 µg/ml soybean trypsin inhibitor, 7 µg/ml pepstatin 
A, 5 µg/ml leupeptin, 0.1 mM benzamidine, 0.5 mM dithiothreitol) and incubated with 
shaking at 4 °C for 30 min. The nuclear extract was then centrifuged for 15 min at 
13,000 g and supernatant was aliquoted and stored at –80 °C. Protein concentration was 
determined by Bio-Rad (Milan, Italy) protein assay kit. 
 
7.2.3 Electrophoretic mobility shift assay (EMSA)  
Double stranded oligonucleotides containing the NF-κB, IRF-1 (5’-
GGAAGCGAAAATGAAATTGACT-3’) and STAT-1α (5’-
CATGTTATGCATATTCCTGTAAGTG-3’) recognition sequences were endlabelled 
with 32P-γ-ATP. Nuclear extracts containing 5 µg protein were incubated for 15 min 
with radiolabeled oligonucleotides (2.5-5.0 x 104 cpm) in 20 µl reaction buffer 
containing 2 µg poly dI-dC, 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM EDTA, 1 
mM DTT, 10% (v/v) glycerol. The specificity of the DNA/protein binding was 
determined by competition reaction in which a 50-fold molar excess of unlabeled wild-
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type, mutant or Sp-1 oligonucleotide was added to the binding reaction 15 min before 
addition of radiolabeled probe. In supershift assay, antibodies reactive to p50 or p65, 
IRF-1 or STAT-1α proteins were added to the reaction mixture 15 min before the 
addition of radiolabeled probe. Nuclear protein-oligonucleotide complexes were 
resolved by electrophoresis on a 6% non-denaturing polyacrylamide gel in 1x TBE 
buffer at 150 V for 2 h at 4 °C. The gel was dried and autoradiographed with 
intensifying screen at –80 °C for 20 h. Subsequently, the relative bands were quantified 
by densitometric scanning of the X-ray films with a GS-700 Imaging Densitometer 
(Bio-Rad, Milan, Italy) and a computer program (Molecular Analyst; IBM). 
 
7.2.4 Western blot analysis 
Immunoblotting analysis of anti-p50, anti-p65, anti-IRF-1, anti-STAT-1α, anti-IκBα, 
anti-IκBβ, anti-iNOS, anti-COX-2, anti-histone and anti-β-actin was performed on 
biopsy. Cytosolic and nuclear fraction proteins were mixed with gel loading buffer (50 
mM Tris, 10% SDS, 10% glycerol, 10% 2-mercaptoethanol, 2 mg/ml of bromophenol) 
in a ratio of 1:1, boiled for 3 min and centrifuged at 10,000 g for 5 min. Protein 
concentration was determined and equivalent amounts (50 µg) of each sample were 
electrophoresed in a 12% discontinuous polyacrylamide minigel. The proteins were 
transferred onto nitro-cellulose membranes, according to the manufacturer’s instructions 
(Bio-Rad). The membranes were saturated by incubation at 4 °C overnight with 10% 
non-fat dry milk in PBS and then incubated with (1:1000) anti-IRF-1, anti-STAT-1α, 
anti-IκBα, anti-IκBβ, anti-iNOS, anti-COX-2 for 1 h at room temperature. The 
membranes were washed three times with 0.05% Triton 100x in PBS and then 
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incubated with anti-rabbit or anti-goat immunoglobulins coupled to peroxidase 
(1:1000). The immunocomplexes were visualized by the ECL chemiluminescence 
method (Amersham, Milan, Italy). The membranes were stripped and re-probed with β-
actin or histone-1 antibody to verify equal loading of proteins. Subsequently, the 
relative bands of p50 and p65, IRF-1 and STAT-1α in nuclear fraction as well as iNOS 
and COX-2 in cytosolic fraction were quantified by densitometric scanning of the X-ray 
films with a GS 700 Imaging Densitometer (Bio-Rad) and a computer program 
(Molecular Analyst, IBM).  
 
7.2.5 Immunofluorescence of p65 subunit 
          Immunological sections of small intestinal biopsy specimens were prepared by  cutting 
paraffinated tissues and subsequently prepared for NF-κB immunofluorescence. The 
slides were gently washed with sterile phosphate-buffered saline (PBS), fixed with 4% 
paraformaldehyde and permeabilized with 0.1% Triton X-100 in PBS for 10 min. The 
slides were incubated with primary antibody (anti-p65) for 1 hr or overnight at room 
temperature, and then washed 3 times in 0.1% Tween 20 in PBS, followed by 30 min 
incubation with fluorescein isothiocyanate (FITC-conjugated secondary antibody, 
Clontech, Inc., Palo Alto, CA). Nuclei were stained with 4’, 6-diamidino-2-
phenylindole (DAPI) for 5 min at room temperature. Coverslips were mounted and 
images were acquired on Nikon TE 300 inverted microscope equipped with Leica DC-
100 colour digital camera. 
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7.3 Cell culture 
The mouse monocyte/macrophage cell line RAW 264.7 was cultured at 37 °C in 
humidified 5 % CO2/95% air in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% foetal bovine serum, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 25 mM Hepes and 5 mM sodium pyruvate. The cells were plated in 24 
culture wells at a density of 2.5 x 105 cells/ml per well or 10 cm diameter culture dishes 
at a density of 3 x 106 cells/ml per dish and allowed to adhere for 2 h. Thereafter the 
medium was replaced with fresh medium and cells were activated with IFN-γ (25 
U/ml). Pt-G (50, 100, 200, 400 and 800 µg/ml), G (50, 100, 200, 400 and 800 µg/ml), 
Bovine Serum Albumin (BSA; 50, 100, 200, 400 and 800 µg/ml), Pt-Z (50, 100, 200, 
400 and 800 µg/ml), Z (50, 100, 200, 400 and 800 µg/ml), Pyrrolidine dithiocarbamate 
(PDTC; 0.1, 1 and 10 µM) or N-α-para-tosyl-L-lysine chloromethyl ketone (TLCK; 1, 
10 and 100 µM) were added to the cells 5 min after IFN-γ challenge, alone or in 
combination. The cell viability was determined by using 3-(4,5-dimethylthiazol-2yl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) conversion assay (D’Acquisto et al., 
2001). Briefly, 100 µl MTT (5 mg/ml in complete DMEM) was added and the cells 
were incubated for an additional 3 h. After this time point the cells were lysed and the 
dark blue crystals solubilized with 500 µl of a solution containing 50% (v:v) N,N-
dimethylformamide, 20% (w:v) SDS with an adjusted pH of 4.5. The optical density 
(OD) of each well was measured with a microplate spectrophotometer (Titertek 
Multiskan MCCC/340) equipped with a 620 nm filter. The cell viability in response to 
treatment with test compounds was calculated as % dead cells = 100 – (OD treated / OD 
control) x 100. 
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7.3.1 Nitrite determination 
NO was measured as nitrite (NO2-, nmol/106 cells) accumulated in the incubation 
medium after 24, 48 and 72 h. A spectrophotometric assay based on the Griess reaction 
was used (D’Acquisto et al., 2001). Briefly, Griess reagent (1% sulphanilamide, 0.1% 
naphthylethylenediamine in phosphoric acid) was added to an equal volume of cell 
culture supernatant and the absorbance at 550 nm was measured after 10 min. The 
nitrite concentration was determined by reference to a standard curve of sodium nitrite. 
 
7.3.2 Cytosolic and nuclear extracts from cultured cells 
Cytosolic and nuclear extracts of macrophages stimulated for 1, 3, 6, 24, 48 and 72 h 
with IFN-γ (25 U/ml) in presence or absence of Pt-G (50, 100, 200, 400 and 800 µg/ml), 
G (50, 100, 200, 400 and 800 µg/ml), PDTC (0.1, 1 and 10 µM) or TLCK (1, 10 and 
100 µM) were prepared as previously described with some modification (D’Acquisto et 
al., 2001). Briefly, harvested cells (3 x 106) were washed two times with ice-cold PBS 
and centrifuged at 180 g for 10 min at 4 °C. The cell pellet was resuspended in 100 µl of 
ice-cold hypotonic lysis buffer (10 mM Hepes, 10 mM KCl, 0.5 mM 
phenylmethylsulphonyfluoride, 1.5 µg/ml soybean trypsin inhibitor, 7 µg/ml pepstatin 
A, 5 µg/ml leupeptin, 0.1 mM benzamidine, 0.5 mM dithiothreitol) and incubated on ice 
for 15 min. The cells were lysed by rapid passage through a syringe needle for five or 
six times and the cytoplasmic fraction was then obtained by centrifugation for 1 min at 
13,000 g. The supernatant containing the cytosolic fraction was removed and stored at –
80°C. The nuclear pellet was resuspended in 60 µl of high salt extraction buffer (20 mM 
Hepes pH 7.9, 10 mM NaCl, 0.2 mM EDTA, 25% v/v glycerol, 0.5 mM 
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phenylmethylsulphonyfluoride, 1.5 µg/ml soybean trypsin inhibitor, 7 µg/ml pepstatin 
A, 5 µg/ml leupeptin, 0.1 mM benzamidine, 0.5 mM dithiothreitol) and incubated with 
shaking at 4 °C for 30 min. The nuclear extract was then centrifuged for 15 min at 
13,000 g and supernatant was aliquoted and stored at –80 °C. Protein concentration was 
determined by Bio-Rad (Milan, Italy) protein assay kit. 
 
7.3.3 Real time quantitative polymerase chain reaction (RT-PCR) 
RAW 264.7 cells (1.0 x 106) were seeded onto 10 cm culture plates in 10 ml of  DMEM 
supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin. IFN-γ (25 
U/ml), G (800 µg/ml), PDTC (10 µM), Gen (25 µM), TB42 (50 µM) were added to the 
cells alone or in combination at 1, 6 and 24 h. Total RNA was prepared from cells by 
using the Rneasy Mini Kit (Qiagen) and subjected to cDNA synthesis with random 
hexanucleotide primers and MultiScribe Reverse Transcriptase (Invitrogen) at 48°C for 
1 h. The cDNA was then amplified in a iCycler Iq Real-Time PCR Detection System 
(Biorad) using iQTMSYBR Green Supermix in triplicate in 25 µl reaction volumes. 
Relative quantification of gene expression was performed using the 2(-Delta Delta 
C(T)) method (Livak and Schmittgen, 2001). Changes in mRNA expression levels were 
calculated following normalization to c-Abl transcripts. The ratios obtained following 
normalization are expressed as fold increase. The primer sequences were as follows: 
c-Abl-F: 5’GGTATGAAGGGAGGGTGTACCA-3’ 
c-Abl-R: 5’GTGAACTAACTCAGCCAGAGTGTTGA-3’ 
NF-κB-F: 5’GGGGATGTGAAGATGTTG-3’ 
NF-κB-R: 5’CCAAGTGCAGAGGTGTCTGA-3’ 
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STAT-1α−F: 5’GTTGCAGCACAACATACGGAA-3’ 
STAT-1α-R: 5’GATCATGGACATCTGTACGGGA-3’ 
IRF-1-F: 5’CAATCACTGGAATGCGGATGA-3’ 
IRF-1-R: 5’TTGTTGATGTCCCAGCCGTG-3’ 
iNOS-F: 5’GAGCATCCCAAGTACGAGTGGT-3’ 
iNOS-R: 5’GGCCACGGCAGGCAG-3’ 
 
7.3.4 Reporter vectors and transfection experiments 
RAW 264.7 macrophages were cultured in DMEM supplemented with 10% fetal bovine 
serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 300 µg/ml L-glutamine. Cells 
(3 x 106) were transfected in triplicate with Lipofectamine™ Reagent (Life 
Technologies, Invitrogen). Each transfection, according to the manufacturer’s 
instructions, was performed with 10 µl of Lipofectamine™ Reagent and 2 µg of piNOS 
CAT1 plasmid (Weisz et al.,1996) plus 0.2 µg of CMV-Luc vector, to correct for 
variations in DNA uptake and transfection efficiency. After 24 h of transfection the cells 
were treated with IFN-γ (25 U/ml), G (800 µg/ml), PDTC (10µM), Gen (25 µM) and 
TB42 (50 µM) alone or in combination for 1, 6 and 24 h. Luciferase activities were then 
measured in a microplate luminometer (EG&G Berthold) as previously described 
(Bevilacqua et al., 1997). CAT gene expression was assessed by measuring the CAT 
protein levels as Reverse transcriptase-polymerase chain reaction (RT-PCR) relative 
activity, by ELISA. (Roche Molecular Biochemicals, Mannheim, Germany). The values 
reported in the figures are the mean of three independent transfection experiments. 
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7.4 Reagents 
32P-γ-ATP was from Amersham (Milan, Italy). Poly dI-dC and T4 polynucleotide kinase 
were from Boehringer-Mannheim (Milan, Italy). Anti-p50, anti-p65, anti-iNOS, anti-
COX-2, anti-IκBα, anti-IκBβ and β-actin antibodies were from Santa Cruz (Milan, 
Italy). Oligonucleotide synthesis was performed to our specifications by Tib Molbiol 
(Boehringer-Mannheim, Genova, Italy). Non-fat dry milk was from Bio-Rad (Milan, 
Italy). DL-dithiothreitol, pepstatin A, leupeptin, benzamidine, 
phenylmethylsulfonilfluoride were from Applichem (Darmstadt, Germany). Pt-G from 
pure bread wheat (Triticum aestivum, var. San Pastore) was kindly supplied by the 
“Istituto Sperimentale per la Cerealicoltura” (Rome, Italy). All other reagents were from 
Sigma (Milan, Italy). Recombinant mouse interferon-γ was from Vinci-Biochem 
(Florence, Italy). 32P- γ -ATP was from Amersham (Milan, Italy). Poly dI-dC was from 
Boehringer-Mannheim (Milan, Italy). Anti-p50, anti-p65, anti-IRF-1, anti-STAT-1α, 
anti-iNOS, anti-IκBα, anti-β-actin and anti-histone1 antibodies was from Santa Cruz 
(Milan, Italy). Phosphate buffer saline was from Celbio (Milan, Italy). Oligonucleotide 
synthesis was performed to our specifications by Tib Molbiol (Boehringer-Mannheim, 
Genova, Italy). Non-fat dry milk was from Bio-Rad (Milan, Italy). CAT ELISA was 
from Molecular Biochemicals (Roche Mannheim, Germany). Lipofectamine™ and 
Reagent iQTMSYBR Green Supermix were from Life Technologies  (Invitrogen, Milan, 
Italy). 
 DL-dithiothreitol, pepstatin A, leupeptin, benzamidine, phenylmethylsulfonilfluoride 
were from Applichem (Darmstadt, Germany). Gliadin, BSA, MTT, PDTC and TLCK as 
well as other reagents were from Sigma (Milan, Italy).  
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7.5 Statistics 
Results are expressed as the means ± S.E.M. of n experiments. Statistical significance 
was calculated by one-way analysis of variance (ANOVA) and Bonferroni-corrected P-
value for multiple comparison test. The level of statistically significant difference was 
defined as P<0.05. Linear associations between variables were assessed by the use of 
standard-least-square linear regression. Correlation coefficient (r) was presented as 
measure of linear association for regression relationship. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 88
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nuclear factor κB is activated in small intestinal mucosa 
of celiac patients 
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8.1  Results 
8.1.1 NF-κB activity is increased in intestinal mucosa of celiac patients 
To detect NF-κB/DNA binding activity, nuclear extracts from biopsy specimens of 
untreated patients, treated patients and normal controls were analyzed by EMSA. As 
shown in Figure 20 A and B, a low basal level of NF-κB/DNA binding activity was 
detected in nuclear extracts from biopsy specimens of controls. The NF-κB/DNA 
binding activity markedly increased in nuclear extracts obtained from biopsy specimens 
of untreated patients, while it significantly decreased in nuclear extracts from biopsy 
specimens of patients treated. The composition of the NF-κB complex  was determined 
by competition and supershift experiments in nuclear extracts from untreated patients. 
The specificity of NF-κB/DNA binding complex was demonstrated by the complete 
displacement of NF-κB/DNA binding in the presence of a 50-fold molar excess of 
unlabeled  NF-κB probe (W.T., 50x) in the competition reaction. In contrast, a 50-fold 
molar excess of unlabeled mutated NF-κB probe (Mut., 50x) or Sp-1 oligonucleotide 
(Sp-1, 50x) had no effect on this DNA-binding activity. The subunit composition of the 
NF-κB complexes was determined by incubating nuclear extracts with specific 
antibodies against p50 or p65 subunits and observing the effects on the electrophoretic 
mobility of NF-κB DNA complexes. Addition of anti-p65 to the binding reaction 
caused the appearance of low mobility complex whereas addition of anti-p50 caused the 
appearance of the faster migrating complex. Concomitant addition of anti-p50 + anti-
p65 to the binding reaction resulted in a marked reduction of the levels of NF-κB 
complexes, suggesting that NF-κB consisted primarily of p50 and p65 dimers (Figure 
20 C). 
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The NF-κB activation was confirmed by immunofluorescence analysis performed on 
these specimens and as well as a larger number of patients and controls. An increased 
nuclear p65 expression was detectable in crypt epithelial cells as well as in lamina 
propria mononuclear cells from untreated patients as compared to treated and controls 
(Figure 21).  
 
8.1.2 Nuclear level of p50 and p65 subunits 
The level of p50 and p65 in nuclear extracts from biopsy specimens was examined by 
Western blot analysis. Biopsy specimens from controls expressed a basal level of p50 
and p65, whereas from untreated patients the levels of p50 and p65 were markedly 
increased as compared with treated patients (Figure 22).  
                     
8.1.3 Cytoplasmic and nuclear level of IκB proteins 
Since NF-κB activation is controlled by inhibitory IκB proteins, we examined the 
presence of IκBα and IκBβ proteins in cytosolic and nuclear extracts from biopsy 
specimens of untreated, treated patients and controls in an attempt to underlying 
mechanisms to sustained activation of NF-κB. In biopsy specimens from untreated 
patients IκBα and even more IκBβ disappeared from the cytosolic fraction whereas high 
levels of IκBα and lower levels of IκBβ were detectable in specimens from treated 
patients and controls. Significant amounts of IκBα and IκBβ were observed in the 
nuclear extracts from biopsy specimens of untreated patients, while lower amounts of 
nuclear IκBα and IκBβ were observed in specimens from treated patients. Basal levels 
of IκBα and IκBβ were present in the nuclear extracts from specimens of controls 
(Figure 23).  
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8.1.4 iNOS and COX-2 protein expression   
iNOS and COX-2 protein level in cytosolic extracts from biopsy specimens were 
determined by Western blot analysis. As shown in Figure 24 a significantly high level 
of either iNOS and COX-2 protein expression was detected in biopsy specimens from 
untreated patients when compared with controls. In biopsy specimens from treated 
patients the level of either iNOS or COX-2 protein expression was significantly reduced 
as compared with untreated patients.  
 
8.1.5 Kinetic analysis of NF-κB activation in cultured biopsy specimens from 
untreated patients  
To determine whether NF-κB activity was also sustained ex vivo, we used an in vitro 
model of mucosal biopsies. Biopsy specimens from untreated patients were cultured 
with medium alone for 0, 2, 4, 6, 12 and 24 h before assessment of NF-κB/DNA 
binding activity. The results in Figure 25 A show that in nuclear extracts from 
specimens cultured for 0, 2, 4 and 6 h NF-κB activity was maintained at high levels, 
while in those cultured for 12 and 24 h NF-κB activity was decreased. When NF-κB 
activity was sustained at high levels, both iNOS and COX-2 protein expression was also 
maintained at high levels. Conversely, reduced NF-κB activity was accompanied by a 
decrease in both iNOS and COX-2 protein expression (Figure 25 B and C, respectively). 
NF-κB/DNA binding activity and either iNOS and COX-2 protein expression were 
correlated (r = 0.99, ***P<0.0001 and r = 0.98, ***P<0.0001, respectively). 
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In addition, to evaluate whether NF-κB activity decreased at 24 h recovered, the 
specimens were incubated with Pt-G (1 mg/ml) for 2, 4 and 6 h. As shown in Figure 26 
A, NF-κB activity increased 6h after addition of Pt-G whereas the levels of either iNOS 
and COX-2 protein expression were at the limit of detection (Figure 26 B and C, 
respectively). These results show that NF-κB activity is sustained in intestinal mucosa 
of patients with untreated CD even 6 h after removal from the causative environment, 
decreases at 12 and 24 h and increases 6 h after the addition of Pt-G.  
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8.2 Discussion 
NF-κB is a transcriptional regulator that mediates key immune and inflammatory 
response (Ghosh et al., 1998). In this report we present evidence for the first time that 
NF-κB is constitutively activated in intestinal mucosa of patients with untreated CD. 
We found that NF-κB/DNA binding activity is significantly greater in biopsy specimens 
from untreated patients than in those from treated patients, indicating that NF-κB 
activation occurs in this mucosal compartment and declines on removal of gluten from 
diet. Levels of p50 and p65 subunits were higher in nuclear extracts from biopsy 
specimens of untreated patients than in those from treated patients. IκBα and IκBβ were 
degraded in the cytosol and present in the nucleus, suggesting that IκBβ plays a role in 
maintaining NF-κB/DNA binding activity in inflamed mucosa of patients with untreated 
CD. It has been reported that agents promote persistent NF-κB activity induce IκBα and 
IκBβ degradation (Bourke et al., 2000; Johnson et al., 1996). IκBα is implicated in 
regulating the persistent NF-κB activation in inflammatory chronic diseases (De Luca et 
al., 1999; Thompson et al., 1995). It has been shown that following degradation of the 
initial pool of IκBβ, newly unphosphorylated synthesized IκBβ, can act as a chaperone 
of NF-κB blocking the inhibitory effect of IκBα in the nucleus and therefore maintain 
NF-κB activity even after IκBα resynthesis (Suyang et al., 1996). Furthermore, other 
studies have demonstrated that the dynamic state of degradation and resynthesis of IκBβ 
may result in the continuous production of hypophosphorylated IκBβ form that is 
unable to mask the nuclear localization signal of RelA, permitting NF-κB/ IκBβ 
complexes to enter into the nucleus and bind DNA (Ghosh et al., 1998; McKinsey et al., 
1997). 
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In this study we demonstrate that IκBβ  is present in the nuclear fraction. At present we 
were unable to determinate whether IκBβ is as part of NF-κB/DNA complex and in 
hypoor unphosphorylated state. Nevertheless, we have found that NF-κB activation 
persists for up 6 h in cultured biopsy specimens from untreated patients and is lower at 
12 and 24 h. In addition, NF-κB activation was correlated with either iNOS and COX-2 
protein expression. Previous studies have shown that iNOS is expressed more in 
enterocytes and COX-2 in the cells of lamina propria (ter Steege et al., 1997; 
Kainulainen et al., 2002). These enzymes catalyzing the synthesis of nitric oxide and 
proinflammatory prostaglandins, respectively, have been shown to be involved in 
disease induction and maintenance (Beckett et al., 1999; Lavo et al., 1990; ter Steege et 
al., 1997; van Straaten et al., 1999). Our finding that both iNOS and COX-2 expression 
is increased in biopsy specimens from untreated patients is in agreement with previous 
observations, although in other studies iNOS and COX-2 appear to play a protective 
role in intestinal injury (Kainulainen et al., 2002; McCafferty et al., 1997; Grisham et 
al., 2002; Newberry et al., 1999; Morteau, 1999). Interestingly, our findings show that 
removal of the inflamed mucosa from the causative environment reduces the expression 
of both iNOS and COX-2, two molecular events downstream of NF-κB activation, and 
suggest that NF-κB activation is diminished in patients with a strict gluten-free diet. 
Moreover, we observed that NF-κB activity is decreased at 24 h and increased in 
cultured biopsy specimens 6 h after the addition of Pt-G. 
Taken together our results show that NF-κB is indeed activated in intestinal mucosa of 
untreated CD patients and suggest a role for IκBβ in regulating the persistent activation 
of NF-κB in this disease. Therefore NF-κB might play a pivotal role in the perpetuation 
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of inflammatory process in CD and even at early stage. NF-κB appears to be an 
important mediator of antigen-induced T cell activation and promotes Th1 subset 
development through the induction of NF-κB-dependent cytokines such as IFN-γ 
(Aronica et al., 1999). 
Secreted products of activated T cells are capable of maintaining the activation of 
nonimmune cells within the lesion, thereby perpetuating the chronic inflammatory 
process (Makarov et al., 2000). Gluten induces activation of mucosal Th1 cells in 
patients with susceptibility of CD, thereby leading to local secretion of high levels of 
interferon-γ, which alone or together with other mediators activates macrophages and 
directly or indirectly damages enterocytes or alter their maturation (Nilsen et al., 1995). 
Activated macrophages secrete cytokines, adhesion molecules, and enzymes whose 
gene expression is known to be transcriptionally regulated by NF-κB (Makarov et al., 
2000). These mediators may contribute to a perpetuation of the inflammatory reaction 
(Sollid, 2000; Beckett et al., 1999). Thus our findings may be of clinical relevance 
because the sustained activation of NF-κB in intestinal mucosa of CD patients leads to 
prolonged induction of inflammatory gene expression and thereby perpetuates the 
chronic inflammatory process. In conclusion, the presence of activated NF-κB in human 
mucosal lesion in CD may yield new insights into the understanding of the pathogenesis 
of this disorder. 
This work has been published in Journal of Molecular Medicine vol 8 pages 373-
379, 2003. Maiuri MC, De Stefano D, Mele G, Fecarotta S, Greco L, Troncone R 
and Carnuccio R. Nuclear factor-κB is activated in small intestinal mucosa of 
celiac patients. 
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Gliadin increases iNOS protein expression in interferon-γ 
RAW 264.7 cells through a mechanism involving NF-κB 
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9.1 Results 
9.1.1 Effect of Pt-G and G on nitrite production by RAW 264.7 cells stimulated 
with IFN-γ for 24 h  
The nitrite production by unstimulated cells was undetectable. The stimulation of cells 
with IFN-γ (25 U/ml) for 24 h resulted in an accumulation of nitrite in the medium. 
Addition of Pt-G (50, 100, 200, 400 and 800 µg/ml) or G (50, 100, 200, 400 and 800 
µg/ml) to the cells increased significantly and in a concentration-dependent manner the 
nitrite production as compared with IFN-γ alone (Figure 27). Enhancement of nitrite 
production by G was greater than that exhibited by Pt-G. In contrast, Pt-G or G added to 
the cells alone, at the same concentrations, did not elicit the nitrite production (data not 
shown). BSA, Pt-Z and Z (50, 100, 200, 400 and 800 µg/ml), used as other food 
antigens, alone or in combination whit IFN-γ had no effect (Table 4). All compounds 
did not affect cell viability (>95%). 
 
 
9.1.2 Effect of PDTC and TLCK on increase of nitrite production and iNOS 
protein expression by Pt-G and G in RAW 264.7 macrophages stimulated with 
IFN-γ for 24 h  
Pt-G (800 µg/ml) or G (800 µg/ml), added to the cells together with IFN-γ (25 U/ml), 
caused an increase of nitrite production (55.4 ± 2.7 and 86.4 ± 3.4, respectively; n = 3) 
as compared with IFN-γ alone (36.0 ± 0.9; n = 3).  
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PDTC or TLCK inhibited significantly the increase of nitrite production induced by Pt-
G and G (Figure 28 A and B). PDTC (0.1, 1 and 10 µM) or TLCK (1, 10 and 100 µM) 
caused a reduction of nitrite production induced by IFN-γ alone (by 31.9 ± 2.1%, 37.5 ± 
1.4%, 66.8 ± 1.8% and 40.0 ± 2.35%, 49.0 ± 3.0%, 64.0 ± 2.1%, respectively; n = 3). 
Upon stimulation with IFN-γ (25 U/ml) for 24 h, cells expressed high level of iNOS 
protein expression as compared with untreated cells. Pt-G (800 µg/ml) or G (800 
µg/ml), added to the cells together with IFN-γ (25 U/ml), increased iNOS protein 
expression (by 1.8 and 3.0 fold, respectively). PDTC (10 µM) or TLCK (100 µM) 
reduced significantly the increase of iNOS protein expression induced by Pt-G (by 80.0 
± 0.1% and 90.0 ± 0.2%, respectively) or by G (by 55.1 ± 0.1% and 65.0 ± 0.2%, 
respectively) (Figure 29). Pt-G and G alone failed to augment the iNOS protein 
expression level (data not shown). 
 
9.1.3 Effect of Pt-G and G on NF-κB/DNA binding activity in RAW 264.7 
macrophages stimulated with IFN-γ for 24 h  
The effects of Pt-G (800 µg/ml) or G (800 µg/ml) on NF-κB/DNA binding activity in 
RAW 264.7 macrophages stimulated with IFN-γ (25 U/ml) for 24 h were evaluated by 
EMSA. A low basal level of NF-κB/DNA binding activity was detected in nuclear 
proteins from unstimulated macrophages. Conversely, a retarded band was clearly 
detected following stimulation with IFN-γ. Pt-G and G caused an increase of NF-
κB/DNA binding activity (by 1.3 and 1.6 fold, respectively) which was reduced by 
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PDTC (10 µM; 90.0 ± 4.5% and 90.0 ± 3.8%, respectively) or TLCK (100 µM; 73.0 ± 
2.0% and 83.5 ± 1.5%, respectively) (Figure 30 A).  
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The composition of the NF-κB complex was determined by competition and supershift 
experiments. The specificity of NF-κB/DNA binding complex was evident by the 
complete displacement of NF-κB/DNA binding in the presence of a 50-fold molar 
excess of unlabelled NF-κB probe in the competition reaction. In contrast a 50-fold 
molar excess of unlabeled mutated NF-κB probe or Sp-1 oligonucleotide had no effect 
on DNA-binding activity. The anti-p50 and anti-p65 antibodies clearly gave rise to a 
characteristic supershift of the retarded complex. Addition of anti-p50 + anti-p65 to the 
binding reaction resulted in a marked reduction of the intensity of NF-κB specific 
bands, suggesting that the NF-κB complex contained p50 and p65 dimers (Figure 30 B).  
 
9.1.4 Effect of Pt-G and G on degradation of IκBα  and nuclear translocation of 
NF-κB subunits in RAW 264.7 macrophages stimulated with IFN-γ for 24 h   
The presence of IκBα in the cytosolic fraction or p50 and p65 subunits in nuclear 
fraction was examined by immunoblotting analysis. Unstimulated cells as well as cells 
treated with Pt-G (800 µg/ml)  or G (800 µg/ml) alone expressed high levels of IκBα in 
the cytosolic fraction and basal levels of p50 and p65 in the nuclear fraction. 
Stimulation of the cells with IFN-γ (25 U/ml) caused a reduction of IκBα band intensity 
which almost disappeared in presence of Pt-G (800 µg/ml) or G (800 µg/ml). PDTC (10 
µM) or TLCK (100 µM) prevented IκBα degradation (Figure 31 A).Upon the 
stimulation with IFN-γ, cells exhibited p50 and p65 high nuclear levels which were 
increased by Pt-G or G. PDTC or TLCK prevented p50 and p65 nuclear translocation 
(Figure 31 B).  
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9.1.5 Effect of Pt-G and G on nitrite production, iNOS protein expression and NF-
κB/DNA binding activity in RAW 264.7 macrophages stimulated with IFN-γ  for 
48 and 72 h 
The cells stimulated with IFN-γ (25 U/ml) for 48 and 72 h caused nitrite accumulation 
which was increased in a significant and concentration-dependent manner by Pt-G (50, 
100, 200, 400 and 800 µg/ml) or G (50, 100, 200, 400 and 800 µg/ml) (Figure 32 A and 
B). Interestingly, Pt-G and G at lower concentrations (50 and 100 µg/ml) enhanced 
significantly (P<0.0001) the nitrite production. In contrast, Pt-G or G added to the cells 
alone, at the same concentrations, did not elicit the nitrite production (data not shown). 
Pt-G (800 µg/ml) or G (800 µg/ml) in combination with IFN-γ also increased both 
iNOS protein expression (by 1.7 and 2.6 fold, at 48 h; by 1.3 and 1.7 fold, at 72 h, 
respectively) and NF-κB/DNA binding activity (by 1.4 and 1.8 fold, at 48 h; by 1.3 and 
1.6 fold, at 72 h, respectively) as compared with IFN-γ alone (Figure 33 A and B). The 
increase of iNOS protein expression was correlated with NF-κB/DNA binding activity 
(r = 0.99,*P<0.05, Pt-G; r = 0.99,*P<0.05, G) at 24, 48 and 72 h.  
 
9.1.6 Effect of Pt-G and G on IRF-1 and STAT-1α DNA/binding activity in RAW 
264.7 macrophages stimulated with IFN-γ:  comparison with kinetic analysis of 
NF-κB DNA/binding activity   
We investigated the enhancing effect of Pt-G and G on IFN-γ-induced IRF-1 or STAT-
1α DNA binding activity.  
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Nuclear extracts from RAW 264.7 cells treated for 1, 3, 6, 24, 48 and 72 h with IFN-
γ (25 U/ml) or both  IFN-γ and Pt-G (800 µg/ml) or G (800 µg/ml) were subjected to 
EMSA using the specific binding elements for each transcription factor. As shown in 
Figure 34, a low basal level of IRF-1 and STAT-1α /DNA binding activity was detected 
in nuclear proteins from unstimulated macrophages. Conversely, a retarded band was 
clearly detected at 1 h after stimulation with IFN-γ. The addition of Pt-G and G to the 
cells caused an increase of band intensity up to 24 h thereafter decreased at 48 h and 72 
h. In contrast, NF-κB/DNA binding activity was evident at 3 h and increased  up to 72 h. 
Pt-G and G alone did not change the binding activity of IRF-1, STAT-1α and NF-κΒ at 
time points considered. These results indicate that the enhancing effect of Pt-G and G 
on IFN-γ-induced iNOS gene expression is mainly mediated through the NF-
κΒ activation.  
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9.2 Discussion 
There is increasing evidence that NO plays important role in the pathogenesis of the 
histologic changes seen in CD (ter Steege et al., 1997; Beckett et al., 1998; Holmegren 
Peterson et al., 1998; Beckett et al., 1999; van Straaten et al., 1999). Recently, it has 
been shown that gluten or gliadin and their proteolytic fragments enhance iNOS mRNA 
level and NO production by mouse peritoneal macrophages stimulated with IFN-γ 
(Tuckovà et al., 2000, 2002). The molecular mechanisms by which gluten/gliadin 
induces iNOS expression and NO production by intestinal mucosa cells in CD and 
cultured activated macrophages have not been investigated. Here, we report that Pt-G 
and G were able to increase significantly and in a concentration-dependent manner NO 
production by RAW 264.7 macrophages stimulated with IFN-γ for 24 h. The increase of 
NO production by Pt-G and G was associated with an increased expression of iNOS 
protein compared with IFN-γ alone. In addition, we found that Pt-G and G increased 
NF-κB/DNA binding activity, IκBα cytosolic degradation and nuclear translocation of 
p50 and p65 subunits. It is particularly interesting to observe that NF-κB/DNA binding 
activity as well as iNOS protein expression and NO production were ulteriorly 
increased by Pt-G and G at 48 and 72 h. In addition, Pt-G and G also at lower 
concentrations were able to increase significantly NO production. G exhibited greater 
effects in comparison with Pt-G. These results show that the type and concentration as 
well as time exposure of gluten derived-peptides induce IFN-γ-stimulated RAW 264.7 
cells to produce high levels of NO and suggest a direct toxic action of gliadin in CD. 
However, Pt-G and G increased iNOS protein expression and NF-κB/DNA binding 
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activity compared with IFN-γ alone. Moreover, the NF-κB activation inhibitors, PDTC 
and TLCK, reduced significantly these effects, thereby indicating that Pt-G and G may 
modulate iNOS protein expression as co-signal with IFN-γ in RAW 264.7 cells through 
NF-κB activation. Besides NF-κB, we also investigated the involvement of IRF-1 and 
STAT-1α in the increase of iNOS expression induced by Pt-G and G in IFN-γ-
stimulated RAW 264.7 cells. Interestingly, the kinetics of IRF-1 and STAT-
1α activation are rapid and decrease compared with NF-κB activation, which is 
persistent. It has been reported that STAT-1α and IRF-1 can cooperate with NF-κB to 
promote synergistically transcriptional activity (Drew et al., 1995; Ohmori et al., 1997; 
Teng et al., 2002). Although the effect of Pt-G and G on IFN-γ-induced iNOS protein 
expression seems to depend on the enhanced activity of all three transcription factors, a 
major role for NF-κB cannot be ruled out. Further studies will be addressed to 
investigate whether this effect is mediated at the molecular level by a cooperation 
between transcription factors. Taken together our results show that Pt-G and G cause a 
time and concentration-dependent increase of IFN-γ-induced NF-κB/DNA binding as 
well as molecular events downstream of NF-κB activation and suggest a role for 
gluten/gliadin in maintaining activated NF-κB in infiltrating lamina propria cells of 
inflamed mucosa of coeliac patients. In CD, it is widely accepted that specific cellular 
and humoral factors are implicated in morphological and functional changes following 
gluten challenge in intestinal mucosa (Auricchio et al., 1990). Nevertheless, some 
reports shown the involvement of non specific immune reaction, caused by direct 
interaction of gluten of innate immune system (Auricchio et al. 1990; Maiuri et al. 
1996; Tuckovà et al. 2000). Gliadin is a lectin that is able to bind glycosylated residues, 
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called “lectinic binding sites” and expressed on various cells, by a non-covalent bound 
(Kolberg and Sollid, 1985; Damjanov, 1987; Amore et al., 1994). Other studies have 
shown that gliadin is able to associate with many proteins, mainly by hydrophobic 
interactions (Farré Castany et al., 1995; Pittschieler et al., 1994; Tuckovà et al., 2000). 
It has been reported that different cell types in response to pro-inflammatory stimuli, 
including IFN-γ, induce the expression of cell surface molecules capable of acting as a 
potent triggers of intracellular activation signals (Marzio et al., 1997). Since Pt-G and G 
alone had no effect, it could be hypothesised that IFN-γ induces the expression of 
macrophage surface molecules able of interacting with Pt-G or G and triggering signal 
transduction pathway. Moreover, gliadin and other lectin fractions of gluten have been 
shown to be potent modulators of leukocyte function, enhancing chemotaxis and 
generation of reactive oxygen species (Roccatello et al., 1990; Amore et al., 1994; 
Rivabene et al., 1999). Several evidences suggest that NF-κB activation may also be 
under the control of oxidant/antioxidant balance (Flohè et al., 1997). The antioxidant 
PDTC is thought to inhibit NF-κB activation by depleting the cells of oxygen radicals, 
whereas TLCK acts by inhibiting proteasome function and hence IκBα degradation 
(Sherman et al., 1993; Kim et al., 1995; Epinat and Gilmore 1999). We found that Pt-G 
and G enhanced IκBα degradation, which was prevented by either PDTC or TLCK 
suggesting that these compounds inhibit NF-κB/DNA binding activity by stabilising 
IκBα in IFN-γ-stimulated RAW 264.7 macrophages. Thus, it is conceivable that Pt-G 
and G in combination with IFN-γ increase NF-κB activation through an oxidant 
mechanism. 
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Moreover, our results show that PDTC and TLCK are able to reduce the increased 
iNOS protein expression and NO production by activated macrophages suggesting that 
NF-κB is responsible for the synergistic effect of Pt-G and G together IFN-γ on NO 
production. High levels of NO are present in serum and urine of children with CD and 
correlated with an increased iNOS expression in the small intestine (ter Steege et al., 
1997; Beckett et al., 1998; Holmegren Peterson et al., 1998; Beckett et al., 1999; van 
Straaten et al., 1999). However, the molecular mechanisms by which NO induces, 
directly or indirectly, injury of the small-intestine in coeliac patients are not clear. 
Excessively produced NO is known to act as a free radical and cause tissue damage (Liu 
and Hotchkiss, 1995). In conclusion, our study provides evidence that the effect of Pt-G 
and G on iNOS protein expression in IFN-γ-treated RAW 264.7 cells is mediated 
through NF-κB and suggests that blockage of NF-κB activation reduces enhancing 
effect of gluten on NO production in inflamed mucosa of celiac patients. 
 
 
 
This work has been published in N-S Arch Pharmacol, vol 368 pages 63-71, 2003. 
Maiuri MC, De Stefano D, Mele G, Iovine B, Bevilacqua MA, Greco L, Auricchio 
S and Carnuccio R. Gliadin increases iNOS gene expression in interferon-γ-
stimulated RAW 264.7 cells through a mechanism involving NF-κB. 
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Role of NF-κB, IRF-1 and STAT-1α transcription factors in the iNOS 
gene induction by gliadin and IFN-γ in RAW 264.7 macrophages 
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10.1 Results 
10.1.1 Effects of PDTC, Gen and TB42 on G-induced increase of nitrite production 
and iNOS protein expression in RAW 264.7 stimulated with IFN-γ for 24 h 
The nitrite production by unstimulated cells was undetectable. The stimulation of cells 
with IFN-γ (25U/ml) for 24 h resulted in an accumulation of nitrite (27.8 ± 4.7 nmol/106 
cells; n = 5) in the medium. G (800 µg/ml) added to the cells together with IFN-γ 
caused a significant increase of the nitrite production (85.9 ± 3.9 nmol/106 cells; n = 5) 
as compared with IFN-γ alone. Treatment of cells with PDTC (0.1, 1 and 10 µM), Gen 
(12.5, 25 and 50 µM) and TB42 (25, 50 and 100 µM) inhibited significantly and in a 
concentration-manner the increase of nitrite production induced by G plus IFN-γ (by 
25.0 ± 1.1%; 70.0 ± 2.2% and 78.2 ± 1.5%; 35.8 ± 3.8%; 59.6 ± 0.9% and 86.9 ± 0.5%; 
2.7 ± 1.4%; 35.2 ± 2.5% and 65.7 ± 1.7%, respectively; n = 3) (Figure 35). Upon 
stimulation with IFN-γ (25 U/ml) for 24 h, cells expressed high level of iNOS protein 
expression as compared with untreated cells. G (800 µg/ml), added to the cells together 
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with IFN-γ (25 U/ml), increased iNOS protein expression compared to IFN-γ alone. 
PDTC (10 µM), Gen (25 µM) and TB42 (50 µM) inhibited significantly the increase of 
iNOS protein expression induced by G plus IFN-γ (by 80.3 ± 0.08%; 35.1 ± 0.75%; 
47.4 ± 1.7%; ***P < 0.0001 respectively; n = 5) (Figure 36). G alone failed to augment 
the iNOS protein expression level. Both EtOH and DMSO vehicles did not affect cell 
viability (data not shown). 
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10.1.2 Effects of PDTC, Gen and TB42 on NF-κB, IRF-1 and STAT-1α activation 
induced by G in RAW 264.7 stimulated with IFN-γ for 24 h 
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We have previously described the activation of NF-κB, IRF-1 and STAT-1α by G and 
IFN-γ combination treatment (Maiuri et al., 2003), here we tested the effects of PDTC 
(10 µM), Gen (25 µM), and TB42 (50 µM) on NF-κB, IRF-1 and STAT-1α/DNA 
binding activity induced by G (800 µg/ml) in RAW 264.7 macrophages stimulated with 
IFN-γ (25 U/ml) for 24 h by EMSA studies using the specific binding elements for each 
transcription factor. A low basal level of NF-κB as well as IRF-1 and STAT-1α/DNA 
binding activity was detected in nuclear proteins from unstimulated macrophages. 
Conversely, a retarded band was clearly detected following stimulation with IFN-γ, the 
intensity of which was markedly increased in extracts from cells exposed to G plus IFN-
γ. Treatment of cells with PDTC or Gen and TB42 caused a significant reduction of 
specific protein-DNA complexes induced by G plus IFN-γ (by 90.3 ± 3.8%; 41.9 ± 
3.7%; 46.5 ± 2.2%; ***P < 0.0001 respectively; n = 6) (Figure 37 A, B and C). 
The composition of protein-DNA binding complexes of respective transcription factors 
was determined by competition. In the reaction of competition the specificity of NF-
κB/DNA binding complexes was evident by the complete displacement of protein-DNA 
binding in the presence of a 50-fold molar excess of unlabeled NF-κB probe. In contrast 
a 50-fold molar excess of unlabeled mutated NF-κB probe or Sp-1 oligonucleotide had 
no effect on DNA binding activity.  
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Addition of either anti-p50 and anti-p65 antibodies to the binding reaction clearly gave 
rise to a characteristic supershift of the retarded complex, suggesting that the NF-κB 
complex contained p50 and p65 dimers (Figure 37 D). Also the specificity of IRF-1 or 
STAT-1α/DNA binding complexes was evident by the complete displacement of 
protein-DNA binding in the presence of a 50-fold molar excess either of unlabeled IRF-
1 and STAT-1α probe, respectively. In contrast a 50-fold molar excess either of 
unlabeled mutated IRF-1 and STAT-1α probe (data not shown) or Sp-1 oligonucleotide 
had no effect on DNA/binding activity. Addition of anti-STAT-1α or anti-IRF-1 
antibody to the binding reaction clearly gave rise to a characteristic supershift of the 
retarded complex, respectively (Figure 37 E and F). Moreover, the presence of p50 and 
p65 as well as IRF-1 and STAT1-α subunits in nuclear fraction was examined by 
immunoblotting analysis. Unstimulated cells expressed basal levels of p50 and p65, 
IRF-1 and STAT1-α. Upon the stimulation with IFN-γ, cells exhibited p50 and p65, 
IRF-1 and STAT-1α high nuclear levels which were increased by G. PDTC prevented 
the nuclear translocation of subunits p50 and p65 (by 50.8 ± 0.2% and 63.5 ± 2.8%, 
***P < 0.0001, vs. IFN-γ plus G , n = 5, respectively) (Figure 38 A). 
Similarly Gen as well as TB42 prevented the nuclear translocation of IRF-1 and STAT-
1-α respectively (by 61.9 ± 0.2% and 44.7 ± 1.6%, ***P < 0.0001 vs. IFN-γ plus G; n = 
5) (Figure 38 B and C). These results show that the PDTC as well as the Gen and TB42 
induce a decrease of NF-κB, IRF-1 and STAT-1α binding to its own specific DNA 
target sequence. 
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10.1.3 Effects PTDC, Gen and TB42 on G-induced increase of iNOS gene 
expression in RAW 264.7 stimulated with IFN-γ for 1, 6 and 24 h 
To explore whether the reduced iNOS protein content observed in cells treated with 
PTDC, Gen and TB42 could be attributed to a reduced gene transcription, first we 
analyzed the expression of iNOS mRNA by RT-PCR analysis. The IFN-γ and G 
combination treatment led to a higher increase of iNOS mRNA levels at 1, 6 and 24 h 
compared to IFN- γ alone. Gen and TB42 treatment reduced iNOS mRNA levels mainly 
at 1 h, whereas PDTC treatment was able to inhibit iNOS mRNA levels at 6 and 24 h 
(Figure 39). To test if iNOS expression was regulated at transcriptional level, we have 
measured the promoter activity of the iNOS gene in cells treated with G (800 ∝g/ml), 
IFN- γ (25 U/ml), PTDC (10 µM), Gen (25 µM), TB42 (50 µM) and their combinations 
for 1, 6 and 24 h. RAW 264.7 cells were transiently transfected with piNOS CAT 
plasmid (Weisz et al., 1996). The results normalized by using CMV-Luc as an internal 
control are reported in Figure 40 and obtained by quantifying CAT activity in 
cellextracts. IFN-γ was efficient in enhancing basal transcription of iNOS promoter 
whereas G alone had no effect (data not shown). The G plus IFN-γ combination 
treatment led to a higher augmentation of promoter activity compared to IFN-γ alone. 
The synergistic induction of iNOS promoter activity was inhibited by Gen and TB42 at 
1 h, whereas it was inhibited by PDTC at 6 and 24 h. These observations indicate that 
the G and IFN-γ combination treatment increases iNOS gene expression through a 
transcriptional mechanism mediated by all three transcription factors at different time 
points. 
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Although a functional analysis of iNOS promoter was not performed, nevertheless the 
inhibitory effects exerted by PDTC, Gen and TB42 on iNOS gene transcription appear 
primarily to involve IRF-1 and STAT-1α at early time points while NF-κB at late time 
points. 
 
10.1.4 Kinetics of the induction of NF-κB/p65, IRF-1 and STAT-1α mRNA 
accumulation by G in RAW 264.7 stimulated with IFN-γ 
Our demonstration that PDTC, Gen and TB42 inhibited the synergistic induction iNOS 
gene transcription by G plus IFN-γ at different time points (Figure 38 and 39), prompted 
us to further investigate the induction of NF-κB/p65, IRF-1 and STAT-1α mRNA 
expression. As shown in Figure 41, the IFN-γ and G combination treatment led to a 
higher increase of NF-κB/p65, IRF-1 and STAT-1α mRNA levels compared to IFN-γ 
alone, but with different kinetics of accumulation. NF-κB/p65 mRNA was induced after 
1 h in an amount which progressively increased up to 24 h (Figure 41 A). In contrast, 
IRF-1 and STAT-1α mRNA levels were highest after 1h, and then declined time 
dependently (Figure 41 B and C). These findings show that the IFN-γ and G 
combination treatment induces a different amount of NF-κB/p65, IRF-1 and STAT-1α 
mRNA level. 
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10.2 Discussion 
The molecular mechanisms by which gluten/gliadin induces iNOS expression and NO 
production by intestinal mucosa cells in celiac disease are unclear. It has been shown 
that gluten or gliadin and their proteolytic fragments enhance iNOS mRNA level and 
NO production by mouse peritoneal macrophages stimulated with IFN-γ (Tuckovà et 
al., 2000;  Tuckovà et al., 2002). 
We have previously reported that G increases iNOS gene expression in IFN-γ-
stimulated RAW 264.7 cells through a mechanism involving NF-κB (Maiuri, et al., 
2003). In the present study, besides NF-κB we have further examined the involvement 
of  IRF-1 and STAT-1α on the synergistic induction of iNOS gene expression by G in 
association with IFN-γ in RAW 264.7 macrophages. The results provided evidence that 
PDTC as well as Gen and TB42, inhibitors of NF-κB, IRF-1 and STAT-1α activation 
respectively, were able to reduce significantly the increase of NO production and iNOS 
protein expression induced by G in RAW 264.7 cells stimulated with IFN-γ for 24 h. 
The well-characterized transcription factors involved in IFN-γ signaling, NF-κB, IRF-1 
and STAT-1α, have been previously demonstrated to play a role in iNOS gene 
regulation (Kamijo et al., 1994; Weisz et al., 1994; Gao et al., 1997 ; Kim et al., 1997 ; 
Saura et al., 1999 ; Xie et al., 1994). Previously, we demonstrated that the G plus IFN-γ 
treatment combination increased the NF-κB, IRF-1 and STAT-1α/DNA binding activity 
in RAW 264.7 cells compared with IFN-γ alone (Maiuri et al., 2003). In the present 
study, EMSA experiments using antibodies against p50 and p65 as well as IRF-1 and 
STAT-1α allowed us to confirm that the formation of specific protein-DNA complexes 
induced by G and IFN-γ involved NF-κB, IRF-1 and STAT-1α. When cells were 
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treated with PDTC, Gen and TB42, the NF-κB, IRF-1 and STAT-1α/DNA binding 
activity as well as respective nuclear subunit level was drastically reduced. Moreover, 
the G plus IFN-γ combination treatment also led to a higher augmentation of iNOS 
promoter activity compared with IFN-γ alone. The synergistic induction of iNOS 
promoter activity was mainly reduced by treatment of cells with Gen and TB42 at 1 h 
and with PDTC at 6 and 24 h. These observations indicate that a synergistic effect of G 
plus IFN-γ on iNOS expression occurs at the transcriptional level and is mediated by 
NF-κB, IRF-1 and STAT-1α. In addition, G plus IFN-γ were found to induce time-
dependently a significant increase of iNOS mRNA accumulation compared with IFN-γ 
alone. 
Gen and TB42 were mainly able to reduce the iNOS mRNA accumulation at 1 h, 
whereas PDTC reduced it at 6 and 24 h. These findings suggest that G may modulate 
iNOS gene expression as co-signal with IFN-γ in RAW 264.7 cells through IRF-1 and 
STAT-1α in the early phase of the induction and NF-κB in the late phase. Interestingly, 
the kinetics of inhibition of iNOS gene expression by PDTC, Gen and TB42 correlated 
with the induction of NF-κB/p65, IRF-1 and STAT-1α mRNA. NF-κB/p65 mRNA 
accumulation was induced after 1 h in an amount which progressively increased up to 
24 h. In contrast, IRF-1 and STAT-1α mRNA levels were highest after 1h, and then 
declined time dependently confirming the contribution of each transcription factor in the 
regulation of iNOS gene expression at different time points. These observations are 
supported by finding that phosphorylated STAT-1α and IRF-1 are degraded by the 
ubiquitin-proteasome pathway decreasing to low levels between 1 and 2 h (Kim and 
Maniatis, 1996). Taken together our results show that PDTC, Gen and TB42 are able to 
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reduce the increased iNOS gene expression by activated macrophages indicating NF-
κB, IRF-1 and STAT-1α as responsible for the synergistic effect of G together with 
IFN-γ on iNOS gene induction. Moreover, the evidence that maximal accumulation 
either of iNOS and transcription factors mRNA occurs when cells are stimulated with a 
combination of G plus IFN-γ suggests a role for G together with IFN-γ as direct 
activator of macrophages in celiac disease (Jelinkova et al., 2004; De Stefano et al., 
2005). The molecular mechanisms that regulate the increase of NF-κB, IRF-1 and 
STAT-1α /DNA binding activity induced in response to G plus IFN-γ remain to be 
determined. Further study of functional analysis of deletion mutants of piNOS and/or 
specific inhibitors of transcription factors will better clarify the cooperative mechanism 
of these transcription factors and even synergistic effect of G plus IFN-γ on iNOS gene 
expression. High levels of NO are present in serum and urine of children with celiac 
disease and correlated with an increased iNOS expression in the small intestine (Beckett 
et al., 1998; ter Steege et al., 1997). We have previously demonstrated that NF-κB is 
activated in small intestinal mucosa of celiac patients and NF-κB/DNA binding was 
correlated with iNOS protein expression (Maiuri et al., 2003). 
However, the molecular mechanisms by which NO induces, directly or indirectly, injury 
of the small-intestine in celiac patients are not clear. Excessively produced NO is known 
to act as a free radical and cause tissue damage (Liu and Hotchkiss, 1995). 
This work has been published in Journal of Molecular Medicine, on line, 2005. De 
Stefano D, Maiuri MC, Iovine B, Ialenti A, Bevilacqua MA and Carnuccio R. The 
role of NF-kappaB, IRF-1, and STAT-1alpha transcription factors in the iNOS 
gene induction by gliadin and IFN-gamma in RAW 264.7 macrophages.  
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11. Conclusions and future perspectives 
Celiac Disease is a complex coordinated pathology. It involves the activation of 
immune system as well as the genesis of a inflammatory pathway and interactions of 
many cellular populations. I have described experimental evidence both ex vivo and in 
vitro showing that some of the events correlated with CD could be regulated by NF-κB, 
IRF-1 and STAT-1α signalling pathway. The results of these investigations report, for 
the first time, NF-κB activation in biopsy specimens from patients with active CD and 
in vitro emphasize iNOS gene induction and subsequent NO production by gliadin plus 
IFN-γ. These events seem to be related to IRF-1 and STAT-1α  activation in the early 
phase and to NF-κB activation in the late phase. These findings may contribute to lead 
to new insights into the molecular mechanism governing the inflammatory process in 
CD. It remains to be elucidated the precise molecular mechanisms by which 
gluten/gliadin interacts with activated macrophages and induces NF-κB, IRF-1 and 
STAT-1α activation even in intestinal mucosa cells in CD. Futhermore, it would also be 
interesting to analyse the signals that lead to cooperation between these transcription 
factors. Therefore, there is an exciting perspective that using agents capable of 
selectively inhibiting these transcription factors or downstream iNOS induction could 
represent a new therapy for CD. 
In conclusion, these findings may provide a better understanding of pathogenic 
mechanisms associated with CD. 
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